<SEC-DOCUMENT>0001193125-17-203516.txt : 20170614
<SEC-HEADER>0001193125-17-203516.hdr.sgml : 20170614
<ACCEPTANCE-DATETIME>20170614161724
ACCESSION NUMBER: 0001193125-17-203516
CONFORMED SUBMISSION TYPE: 424B5
PUBLIC DOCUMENT COUNT: 4
FILED AS OF DATE: 20170614
DATE AS OF CHANGE: 20170614
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
CENTRAL INDEX KEY: 0001299130
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 161590339
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 424B5
SEC ACT: 1933 Act
SEC FILE NUMBER: 333-199891
FILM NUMBER: 17911331
BUSINESS ADDRESS:
STREET 1: 1305 O'BRIEN DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
BUSINESS PHONE: 650-521-8000
MAIL ADDRESS:
STREET 1: 1305 O'BRIEN DRIVE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
FORMER COMPANY:
FORMER CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA INC
DATE OF NAME CHANGE: 20050829
FORMER COMPANY:
FORMER CONFORMED NAME: NANOFLUIDICS INC
DATE OF NAME CHANGE: 20040729
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d402129d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
<BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5) <BR> Registration No. 333-199891<BR><BR> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#de1a1e"><B>SUBJECT TO COMPLETION, DATED JUNE 14, 2017 </B></FONT></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Arial Narrow"><FONT COLOR="#de1a1e"><B>This preliminary prospectus supplement and accompanying prospectus
relate to an effective registration statement under the Securities Act of 1933, as amended, but the information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying
prospectus are not an offer to sell the securities, and we are not soliciting an offer to buy these securities, in any jurisdiction where the offer or sale is not permitted. </B></FONT></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(To Prospectus dated November 21, 2014) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Shares </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt"> </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">
<IMG SRC="g402129g49c21.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Pacific Biosciences of California, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%"> </P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are offering
shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The NASDAQ Global Select
Market under the symbol “PACB.” On June 13, 2017, the last reported sale price for our common stock on The NASDAQ Global Select Market was $3.45 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>An investment in our common stock involves a high degree of risk. You should carefully consider the information under the heading “<A HREF="#suprom402129_3">Risk
Factors</A>” beginning on page S-3 of this prospectus supplement and in the documents incorporated by reference into this prospectus supplement before you invest in our securities.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">
<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="8" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> </P></TD>
<TD> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Per Share</B></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B> Total </B></TD>
<TD VALIGN="bottom"> </TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="8" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00pt solid #000000"> </P></TD>
<TD> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public Offering Price</P></TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> </TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> </TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting Discounts and
Commissions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to Pacific Biosciences of California, Inc. (before expenses)</P></TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="8" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> </P></TD>
<TD> </TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP> </TD>
<TD ALIGN="left" VALIGN="top">See “Underwriting” beginning in page S-14 of this prospectus supplement for additional information regarding the compensation payable to the underwriter. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delivery of the shares of common stock is expected to be made on or about June , 2017. We have granted the underwriter
an option for a period of 30 days to purchase up to an additional shares of our common stock. If the underwriter exercises the option in full, the total underwriting discounts and commissions payable
by us will be $ , and the total proceeds to us, before expenses, will be $ . </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><I>Sole Book-Running Manager </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Cantor Fitzgerald & Co. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is June , 2017.</B> </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">
<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Preliminary Prospectus Supplement</B></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_1">About This Prospectus Supplement</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-ii</FONT></TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_2">Summary</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-3</FONT></TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_4">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-6</FONT></TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-7</FONT></TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_6">Price Range of Our Common Stock</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-8</FONT></TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_7">Dividend Policy</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-8</FONT></TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_8">Dilution</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-9</FONT></TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_9">Material U.S. Tax Considerations for Non-U.S. Holders</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-10</FONT></TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_10">Underwriting</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-14</FONT></TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_11">Legal Matters</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-21</FONT></TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_12">Experts</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-21</FONT></TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_13">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-21</FONT></TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_14">Incorporation Incorporated by Reference</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-22</FONT></TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Prospectus</B></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_16">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_17">Risk Factors</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_18">Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_19">Ratio of Earnings to Fixed Charges</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_20">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_21">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_22">Description of the Depositary Shares</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_23">Description of the Warrants</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_24">Description of the Debt Securities</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_25">Description of the Units</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_26">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_27">Legal Matters</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_28">Experts</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_29">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_30">Information Incorporated by Reference</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
</TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus relate to the offering of our common stock. Before buying any of the common stock
that we are offering, we urge you to carefully read this prospectus supplement, the accompanying prospectus, any free writing prospectus that we have authorized for use in connection with this offering, and the information incorporated by reference
as described under the headings “Where You Can Find More Information” and “Information Incorporated by Reference” in this prospectus supplement. These documents contain important information that you should consider when making
your investment decision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document is comprised of two parts. The first part is this prospectus supplement, which describes the
specific terms of this offering and also adds to, and updates information contained in, the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. The second part, the
accompanying prospectus, including the documents incorporated by reference into the accompanying prospectus, provides more general information, some of which may not apply to this offering. Generally, when we refer to this prospectus, we are
referring to the combined document consisting of this prospectus supplement and the accompanying prospectus. In this prospectus supplement, as permitted by law, we “incorporate by reference” information from other documents that we file
with the Securities and Exchange Commission, or the SEC. This means that we can disclose important information to you by referring to those documents. The information incorporated by reference is considered to be a part of this prospectus supplement
and the accompanying prospectus and should be read with the same care. When we make future filings with the SEC to update the information contained in documents that have been incorporated by reference, the information included or incorporated by
reference in this prospectus supplement is considered to be automatically updated and superseded. In other words, in case of a conflict or inconsistency between information contained in this prospectus supplement and information in the accompanying
prospectus or incorporated by reference into this prospectus supplement, you should rely on the information contained in the document that was filed later. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in, or incorporated by reference into, this prospectus supplement, the accompanying
prospectus, and in any free writing prospectus that we have authorized for use in connection with this offering. We have not authorized any other person to provide you with different information. We are not making an offer to sell or soliciting an
offer to buy our securities in any jurisdiction in which an offer or solicitation is not authorized or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or
solicitation. You should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference into this prospectus supplement and the accompanying prospectus, and in any free
writing prospectus that we have authorized for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations, and prospects may have changed since those
dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context otherwise requires, as used in this prospectus supplement, “we,” “us,” “Pacific
Biosciences,” “PacBio,” “the Company” and “our” refer to Pacific Biosciences of California, Inc., a Delaware corporation. The names “Pacific Biosciences,” “PacBio,” “SMRT,”
“SMRTbell” and our logo are our trademarks. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-ii </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_2"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information contained elsewhere or incorporated by reference in this prospectus supplement and does not
contain all the information that you need to consider in making your investment decision. This summary sets forth the material terms of this offering, but does not contain all of the information you should consider before investing in our common
stock. You should carefully read this entire prospectus supplement, the accompanying prospectus and any free writing prospectus, as well as the information to which we refer you and the information incorporated by reference herein, before deciding
whether to invest in shares of our common stock. You should pay special attention to the “Risk Factors” section of this prospectus supplement to determine whether an investment in the shares of our common stock is appropriate for you.</I>
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We design, develop and
manufacture sequencing systems to help scientists resolve genetically complex problems. Based on our novel Single Molecule, Real-Time (SMRT<SUP STYLE="font-size:85%; vertical-align:top">®</SUP>) Sequencing technology, our products enable: de
novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find novel
genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. Our technology combines very high consensus accuracy and long
read lengths with the ability to detect real-time kinetic information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2015, we announced that we had launched a new nucleic
acid sequencing platform, the PacBio Sequel™ System (the “Sequel System”), which will provide higher throughput, more scalability, a reduced footprint and lower sequencing project costs compared to the PacBio<SUP
STYLE="font-size:85%; vertical-align:top">®</SUP> RS II System, while maintaining the existing benefits of our SMRT Technology. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent
Developments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to that certain Controlled Equity Offering<SUP STYLE="font-size:85%; vertical-align:top">SM</SUP> Sales
Agreement, dated October 5, 2012, as amended on November 8, 2013, as further amended on February 3, 2015 (as amended, the “Sales Agreement”), by and between us and Cantor Fitzgerald & Co. (“Cantor”), we may offer and sell,
from time to time, shares of our common stock through Cantor, acting as agent, through an “at the market offering” as defined in Rule 415(a)(4) (the “ATM Offering”) promulgated under the Securities Act of 1933, as amended. On
February 2, 2017, pursuant to the ATM Offering, we filed a prospectus supplement pursuant to which we may offer and sell, from time to time, shares of our common stock having an aggregate offering price of up to $60.0 million through Cantor (the
“ATM Prospectus Supplement”). From April 1, 2017 to June 7, 2017, we issued 3,170,931 shares of our common stock at an average price of $3.86 per share through the ATM Prospectus Supplement, resulting in net proceeds of approximately $11.9
million. We paid a commission equal to 3% of the gross proceeds from the sale of shares of our common stock under the ATM Prospectus Supplement. We terminated the ATM Prospectus Supplement on June 14, 2017, but the Sales Agreement remains in full
force and effect. As of June 12, 2017, we had 97,701,431 shares of common stock outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pacific Biosciences of California, Inc., formerly Nanofluidics, Inc., was incorporated in the State of Delaware in 2000. Our executive offices
are located at 1305 O’Brien Drive, Menlo Park, California 94025, and our telephone number is (650) 521-8000. We maintain a website at<I> www.pacb.com</I> where general information about us is available. Our website, and the
information contained therein, is not a part of this prospectus supplement. </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt"> </P></div><br clear="All"></div><br clear="All">
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">
<TR>
<TD WIDTH="28%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="69%"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock offered by us</P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> shares.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding
immediately after this offering</P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="top"> shares (or shares if the underwriters
exercise their option to purchase additional shares in full).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares</P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="top"> shares.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Use of Proceeds</P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="top">We currently intend to use the net proceeds from this offering, if any, for general corporate purposes, including capital expenditures and working capital. We may also use a portion of the net proceeds from this offering to acquire
or invest in complementary businesses, technologies, product candidates or other intellectual property. See “Use of Proceeds” on page <FONT STYLE="white-space:nowrap">S-7</FONT> of this prospectus supplement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk Factors</P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="top">Before deciding to invest in shares of our common stock, you should read carefully the risks set forth under the caption “Risk Factors” beginning on page S-3 of this prospectus supplement and the risks described in our
annual and periodic reports incorporated by reference into this prospectus supplement and the accompanying prospectus.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NASDAQ Global Select Market symbol</P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="top">“PACB”</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of our common stock to be outstanding immediately after this offering is based upon
93,540,431 shares outstanding as of March 31, 2017. The number of shares does not include the shares subject to the underwriters’ option to purchase additional shares and also excludes the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">26,656,509 shares of our common stock issuable upon the exercise of stock options outstanding as of March 31, 2017, with a weighted average exercise price of $6.11 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">1,841,595 shares of our common stock reserved for future issuance under our Employee Stock Purchase Plan as of March 31, 2017; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">an aggregate of 7,199,007 shares of our common stock reserved for issuance under our 2010 Equity Incentive Plan and our 2010 Outside Director Equity Incentive Plan; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">an aggregate of 3,170,931 shares of our common stock issued pursuant to our “at-the-market” offering program subsequent to March 31, 2017. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise indicated, all information in this prospectus supplement assumes no exercise or settlement of the outstanding options
other equity awards described above and no exercise of the underwriter’s option to purchase additional shares of common stock. </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt"> </P></div><br clear="All"></div><br clear="All">
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>An investment in the shares of our common stock involves a high degree of risk. In addition to the other information contained in this
prospectus supplement, the accompanying prospectus and the documents that we incorporate by reference, you should carefully consider the risks discussed below and under the section entitled “Risk Factors” contained in our Annual Report on
Form 10-K for the year ended December 31, 2016 and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 before making a decision about investing in our securities. The risks and uncertainties discussed below, in our
Annual Report on Form 10-K for the fiscal year ended December 31, 2016, and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 are not the only ones facing us. Additional risks and uncertainties not presently known
to us, or that we currently see as immaterial, may also harm our business. If any of these risks occur, our business, financial condition and operating results could be harmed, the trading price of our common stock could decline and you could lose
part or all of your investment. This prospectus supplement also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a
result of certain factors, including the risks faced by us described below and elsewhere in this prospectus supplement and the accompanying prospectus.</I> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to This Offering and our Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The price of our common stock has been, is, and may continue to be highly volatile, which may make it difficult for stockholders to sell our common stock
when desired or at attractive prices. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of our common stock is highly volatile, and we expect it to continue to be
volatile for the foreseeable future in response to many risk factors listed in this section, and others beyond our control, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">actual or anticipated fluctuations in our financial condition and operating results; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">announcements of technological innovations by us or our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">announcements by our customers, partners or suppliers relating directly or indirectly to our products, services or technologies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">overall conditions in our industry and market; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">addition or loss of significant customers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">changes in laws or regulations applicable to our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">actual or anticipated changes in our growth rate relative to our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, capital commitments or achievement of significant milestones; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">additions or departures of key personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">competition from existing products or new products that may emerge; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">issuance of new or updated research or reports by securities analysts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">fluctuations in the valuation of companies perceived by investors to be comparable to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">disputes or other developments related to proprietary rights, including patents, litigation matters or our ability to obtain intellectual property protection for our technologies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">announcement or expectation of additional financing efforts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">sales of our common stock by us or our stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">stock price and volume fluctuations attributable to inconsistent trading volume levels of our shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">reports, guidance and ratings issued by securities or industry analysts; and </TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">general economic and market conditions. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of the forgoing occurs, it would cause our
stock price or trading volume to decline. Stock markets in general and the market for companies in our industry in particular have experienced price and volume fluctuations that have affected and continue to affect the market prices of equity
securities of many companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad market and industry fluctuations, as well as general economic, political and market
conditions such as recessions, interest rate changes or international currency fluctuations, may negatively impact the market price of our common stock. You may not realize any return on your investment in us and may lose some or all of your
investment. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We have been a party to this type of litigation in the past and may be the target of this
type of litigation again in the future. Securities litigation against us could result in substantial costs and divert our management’s attention from other business concerns, which could seriously harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our operating results and financial performance do not meet the guidance that we have provided to the public, our stock price may decline.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We provide public guidance on our expected operating and financial results. Although we believe that this guidance provides our
stockholders, investors and analysts with a better understanding of our expectations for the future, such guidance is comprised of forward-looking statements which are subject to the risks and uncertainties described in this report and in our other
public filings and public statements. Our actual results may not meet the guidance we have provided. If our operating or financial results do not meet our guidance or the expectations of investment analysts, our stock price may decline. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of ownership by our principal stockholders may result in control by such stockholders of the composition of our board of directors.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our existing significant stockholders, executive officers, directors and their affiliates beneficially own a significant number of
our outstanding shares of common stock. As a result, these stockholders will be able to exercise a significant level of control over all matters requiring stockholder approval, including the election of directors. This control could have the effect
of delaying or preventing a change of control of our company or changes in management and will make the approval of certain transactions difficult or impossible without the support of these stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our large number of authorized but unissued shares of common stock may potentially dilute existing stockholders’ stockholdings. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have a significant number of authorized but unissued shares of common stock. Our board of directors may issue shares of common stock from this authorized
but unissued pool from time to time without stockholder approval, resulting in the dilution of our existing stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience
immediate dilution. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given effect to the issuance of common stock in this offering, the receipt of the expected net proceeds and
the use of those proceeds, this offering may have a dilutive effect on our expected net income available to our common stockholders per share and funds from operations per share. The actual amount of dilution cannot be determined at this time and
will be based on a number of factors. See “Dilution” on page S-9 of this prospectus supplement for additional information regarding potential dilution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience future dilution as a result of future equity offerings. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that we raise additional funds through the sale of equity or securities that are convertible into or exchangeable for, or that
represent the right to receive, common stock or substantially similar securities, the </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issuance of such securities will result in dilution to our stockholders. We may sell shares or other securities in any other offering at a price per share that is less than the price per share
paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock, or securities that
are convertible into or exchangeable for, or that represent the right to receive, common stock or substantially similar securities, in future transactions may be higher or lower than the price per share paid by investors in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Management will have broad discretion as to the use of the proceeds from this offering and may not use the proceeds effectively. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we have not designated the amount of net proceeds from this offering to be used for any particular purpose, our management will have
broad discretion as to the application of the net proceeds from this offering and could use them for purposes other than those contemplated at the time of the offering. Our management may use the net proceeds for corporate purposes that may not
improve our financial condition or market value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not intend to pay dividends for the foreseeable future. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any dividends on our common stock and do not intend to pay any dividends in the foreseeable future. In addition,
the terms of our existing debt agreement restrict our ability to pay dividends on our common stock. We anticipate that we will retain all of our future earnings for use in the operation of our business and for general corporate purposes. Any
determination to pay dividends in the future will be at the discretion of our board of directors. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any future
gains on their investments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be
beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management and limit the market price of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions in our certificate of incorporation and bylaws, as amended and restated, may have the effect of delaying or preventing a change of
control or changes in our management. Our amended and restated certificate of incorporation and bylaws include provisions that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">authorize our board of directors to issue, without further action by the stockholders, up to 50,000,000 shares of undesignated preferred stock and up to approximately 1,000,000,000 shares of authorized but unissued
shares of common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">specify that special meetings of our stockholders can be called only by our board of directors, the Chairman of the Board, the Chief Executive Officer or the President; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">establish that our board of directors is divided into three classes, Class I, Class II and Class III, with each class serving staggered terms; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">provide that our directors may be removed only for cause; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more
difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203
of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_4"></A>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus, the documents we have filed with the SEC that are incorporated by reference and any
free writing prospectus that we have authorized for use in connection with this offering contain “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act
of 1934, as amended, or the Exchange Act, that involve risks and uncertainties, as well as assumptions, that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such
forward-looking statements. Forward-looking statements generally are identified by the words “may,” “will,” “project,” “might,” “expects,” “anticipates,” “believes,”
“intends,” “estimates,” “should,” “could,” “would,” “strategy,” “goal,” “seek,” “potential,” “predict,” “plan,” “continue,”
“pursue,” or the negative of these words or other words or expressions of similar meaning. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. For example, forward-looking
statements include statements about our future financial and operating results, plans, expectations for potential research and development payments, milestone payments, royalty payments, cash burn rates, timing of achieving positive cash flow,
potential revenue and profits of a combined company or from license agreements, costs and expenses, interest rates, outcome of contingencies, financial condition, liquidity, business strategies and cost savings, any statements of the plans,
strategies and objectives of management for future operations, any statements concerning our product candidates and product development, any statements regarding future economic conditions or performance, statements of belief and any statement of
assumptions underlying any of the foregoing. We discuss in greater detail, and incorporate by reference into this prospectus supplement and the accompanying prospectus in their entirety, many of these risks and uncertainties under the heading
“Risk Factors” beginning on page S-3 of this prospectus supplement. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our
forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of these risks or uncertainties materializes or any of these assumptions proves incorrect, our results
could differ materially from the expectations in these statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The forward-looking statements included in this prospectus supplement
are made only as of the date of this prospectus supplement, and we are not under any obligation to update our respective forward-looking statements and do not intend to do so. You should not assume that the information contained in this prospectus
supplement or the accompanying prospectus is accurate as of any date other than the date on the front of this prospectus supplement or the accompanying prospectus, as applicable, or that any information incorporated by reference into this prospectus
supplement or the accompanying prospectus is accurate as of any date other than the date of the document so incorporated by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus supplement, the accompanying prospectus, the documents we have filed with the SEC that are incorporated by
reference and any free writing prospectus that we have authorized for use in connection with this offering completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the
forward-looking statements in the foregoing documents by these cautionary statements. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate the net proceeds from the sale of common stock by us in this offering will be approximately
$ million (or approximately $ million if the underwriters’ option to purchase additional shares
is exercised in full) after deducting the underwriting discount and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently intend to use
the net proceeds from this offering, if any, for general corporate purposes, including capital expenditures and working capital. We may also use a portion of the net proceeds from this offering to acquire or invest in complementary businesses,
technologies, product candidates or other intellectual property, although we have no present commitments or agreements to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of
the date of this prospectus supplement, we cannot specify with certainty all of the particular uses for the net proceeds to us from this offering. As a result, our management will have broad discretion regarding the timing and application of the net
proceeds from this offering. Pending the uses described above, we intend to invest the net proceeds in interest-bearing, investment-grade securities. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_6"></A>PRICE RANGE OF OUR COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock trades on The NASDAQ Global Select Market under the symbol “PACB.” The following table sets forth the range of high
and low prices for our common stock as reported on The NASDAQ Global Select Market for the periods indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">
<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom"> </TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Year Ended December 31, 2015:</B></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First quarter</P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 8.78</TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.38</TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second quarter</P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">6.55</TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">5.11</TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third quarter</P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">5.90</TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">3.58</TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth quarter</P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">14.00</TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">4.26</TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Year Ended December 31, 2016:</B></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First quarter</P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13.98</TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.50</TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second quarter</P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">10.75</TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">6.79</TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third quarter</P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">9.50</TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">6.76</TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth quarter</P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">9.28</TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">3.76</TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Year Ending December 31, 2017:</B></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First quarter</P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 5.74</TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.78</TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second quarter (through June 13, 2017)</P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">5.43</TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">3.20</TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The last reported sale price of our common stock on The NASDAQ Global Select Market on June 13, 2017 was
$3.45 per share. Past price performance is not indicative of future price performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_7"></A>DIVIDEND POLICY
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never paid or declared any cash dividends on our common stock and do not anticipate paying cash dividends in the foreseeable
future. In addition, the terms of our existing debt agreement restrict our ability to pay dividends on our common stock. We anticipate that we will retain all of our future earnings for use in the operation of our business and for general corporate
purposes. Any determination to pay dividends in the future will be at the discretion of our board of directors. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to
realize any future gains on their investments. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_8"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net tangible book value of our common stock on March 31, 2017 was approximately $69.2 million, or approximately $ 0.74 per
share. Net tangible book value per share is equal to the amount of our total tangible assets, less total liabilities, divided by the number of shares of common stock outstanding. Dilution in net tangible book value per share represents the
difference between the amount per share paid by purchasers of shares of common stock in this offering and the net tangible book value per share of our common stock immediately afterwards. After giving effect to the sale by us of
shares of common stock in this offering at the public offering price of $ per share and after deducting the underwriting discount and estimated offering
expenses payable by us, our as adjusted net tangible book value at March 31, 2017 would have been approximately $ million, or $ per share. This
represents an immediate increase in net tangible book value of $ per share to existing stockholders and an immediate dilution of $ per share to new
investors purchasing shares of common stock in this offering. The following table illustrates this dilution: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">
<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price per share</P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> </TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share as of March 31, 2017</P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.74</TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase per share attributable to new investors after giving effect to the offering</P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"> </P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"> </P></TD>
<TD> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share after giving effect to the offering</P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"> </P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"> </P></TD>
<TD> </TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution in net tangible book value per share to new investors</P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> </P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"> </P></TD>
<TD> </TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the underwriters’ option to purchase additional shares is exercised in full to purchase additional
shares of common stock in this offering, based upon the public offering price of $ , the as adjusted net tangible book value per share after giving effect to the offering would be
$ per share, the increase in the net tangible book value per share to existing stockholders would be $ per share and the dilution to the new investors
would be $ per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing table does not take into effect further dilution to
new investors that could occur upon the exercise of outstanding options having a per share exercise price less than the offering price per share in this offering or the release of restricted stock units. The foregoing table is based upon 93,540,431
shares outstanding as of March 31, 2017 and does not include the shares subject to the underwriters’ option to purchase additional shares and also excludes the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">26,656,509 shares of our common stock issuable upon the exercise of stock options outstanding as of March 31, 2017, with a weighted average exercise price of $6.11 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">1,841,595 shares of our common stock reserved for future issuance under our Employee Stock Purchase Plan as of March 31, 2017; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">an aggregate of 7,199,007 shares of our common stock reserved for issuance under our 2010 Equity Incentive Plan and our 2010 Outside Director Equity Incentive Plan; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">an aggregate of 3,170,931 shares of our common stock issued pursuant to our “at-the-market” offering program subsequent to March 31, 2017. </TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_9"></A>MATERIAL U.S. FEDERAL INCOME AND ESTATE TAX CONSIDERATIONS FOR <FONT
STYLE="white-space:nowrap">NON-U.S. HOLDERS</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material U.S. federal income and estate tax
consequences of the ownership and disposition of our common stock to non-U.S. holders, but does not purport to be a complete analysis of all the potential tax considerations relating thereto. This summary is based upon the provisions of the Internal
Revenue Code of 1986, as amended, or the Code, Treasury regulations promulgated thereunder, administrative rulings and judicial decisions, all as of the date hereof. These authorities may be changed, possibly retroactively, so as to result in U.S.
federal income tax or estate tax consequences different from those set forth below. We have not sought any ruling from the Internal Revenue Service, or the IRS, with respect to the statements made and the conclusions reached in the following
summary, and there can be no assurance that the IRS will agree with such statements and conclusions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This summary also does not address
the tax considerations arising under the laws of any State of the United States or any local, non-U.S. or other taxing jurisdiction or under U.S. federal non-income tax laws, such as gift and estate tax laws, except to the limited extent set forth
below, or under any applicable tax treaty. In addition, this discussion does not address any potential application of the Medicare contribution tax on net investment income or any tax considerations applicable to an investor’s particular
circumstances or to investors that may be subject to special tax rules, including, without limitation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">banks, insurance companies or other financial institutions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">persons subject to the alternative minimum tax; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">tax-exempt organizations or accounts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">controlled foreign corporations, passive foreign investment companies or corporations that accumulate earnings to avoid U.S. federal income tax; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">dealers in securities or currencies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">traders in securities that elect to use a mark-to-market method of accounting for their securities holdings; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">persons that own, or are deemed to own, more than five percent of our capital stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">certain former citizens or long-term residents of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">persons who hold our common stock as a position in a hedging transaction, “straddle,” “conversion transaction” or other risk reduction transaction; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">persons who do not hold our common stock as a capital asset within the meaning of Section 1221 of the Code (generally, for investment purposes); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as compensation; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">persons deemed to sell our common stock under the constructive sale provisions of the Code. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if a partnership, including any entity or arrangement, domestic or foreign, classified as a partnership for U.S. federal income
tax purposes, holds our common stock, the tax treatment of a partner generally will depend on the status of the partner and the activities of the partnership. Accordingly, partnerships that hold our common stock, and partners in such partnerships,
should consult their tax advisors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>You are urged to consult your tax advisor with respect to the application of the U.S. federal
income tax laws to your particular situation, as well as any tax consequences of the purchase, ownership and disposition of our common stock arising under the U.S. federal estate or gift tax rules or under the laws of any State of the United States
or any local, non-U.S. or other taxing jurisdiction, or under any applicable tax treaty. </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Non-U.S. Holder Defined </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this discussion, you are a non-U.S. holder if you are a beneficial owner of our common stock that is not, for U.S. federal
income tax purposes, any of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">an individual who is a citizen or resident of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">a corporation or other entity taxable as a corporation created or organized in the United States or under the laws of the United States, any State thereof or the District of Columbia; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">an estate whose income is subject to U.S. federal income tax regardless of its source; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">a trust (x) the administration of which is subject to the primary supervision of a U.S. court and that has one or more U.S. persons who have the authority to control all substantial decisions of the trust or
(y) that has made an election to be treated as a U.S. person; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">an entity or arrangement, domestic or foreign, classified as a partnership for U.S. federal income tax purposes. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described under
“Dividend Policy,” above, we have not and do not anticipate paying dividends. However, if we make distributions on our common stock, those payments will constitute dividends for U.S. tax purposes to the extent paid from our current or
accumulated earnings and profits, as determined under U.S. federal income tax principles. To the extent those distributions exceed both our current and our accumulated earnings and profits, they will constitute a return of capital and will first
reduce your basis in our common stock (determined separately with respect to each share of our common stock), but not below zero, and then will be treated as gain from the sale of that stock (subject to tax as described below under “<I>Gain on
Sale or Other Disposition of Common Stock</I>”). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussion below on effectively connected income, any dividend paid
to you generally will be subject to U.S. withholding tax either at a rate of 30% of the gross amount of the dividend or such lower rate as may be specified by an applicable income tax treaty. In order to receive a reduced treaty rate, you must
provide us with an IRS Form W-8BEN or IRS Form W-8BEN-E (including, if required, a foreign or U.S. taxpayer identification number) or other appropriate version of IRS Form W-8 certifying qualification for the reduced rate. If you hold our common
stock through a financial institution or other agent acting on your behalf, you will be required to provide appropriate documentation to the agent, who then will be required to provide the required certification to us or our paying agent, either
directly or through other intermediaries. You should consult your tax advisor regarding your entitlement to benefits under any applicable income tax treaty. If you are eligible for a reduced rate of withholding tax pursuant to a tax treaty, you may
be able to obtain a refund of any excess amounts currently withheld if you timely file an appropriate claim for refund with the IRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends received by you that are effectively connected with your conduct of a U.S. trade or business (and, if an income tax treaty applies,
are attributable to a permanent establishment or fixed base maintained by you in the United States) generally are exempt from such withholding tax. In order to obtain this exemption, you must provide us with an IRS Form W-8ECI properly certifying
such exemption. Such effectively connected dividends, although not subject to withholding tax, are taxed at the same graduated rates applicable to U.S. persons, net of certain deductions and credits, subject to an applicable income tax treaty
providing otherwise. In addition, if you are a corporate non-U.S. holder, dividends you receive that are effectively connected with your conduct of a U.S. trade or business (and, if an income tax treaty applies, are attributable to a permanent
establishment or fixed base maintained by you in the United States) may also be subject to a branch profits tax at a rate of 30% or such lower rate as may be specified by an applicable income tax treaty. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on Sale or Other Disposition of Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussions of backup withholding and FATCA below, you generally will not be required to pay U.S. federal income tax on any gain
realized upon the sale or other disposition of our common stock unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the gain is effectively connected with your conduct of a U.S. trade or business (and, if an income tax treaty applies, the gain is attributable to a permanent establishment or fixed base maintained by you in the United
States), in which case you will be required to pay tax on the net gain derived from the sale under regular graduated U.S. federal income tax rates, and for a non-U.S. holder that is a corporation, such non-U.S. holder may be subject to the branch
profits tax at a 30% rate on such effectively connected gain or such lower rate as may be specified by an applicable income tax treaty; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">you are an individual who is present in the United States for a period or periods aggregating 183 days or more during the calendar year in which the sale or disposition occurs and certain other conditions are met, in
which case you will be required to pay a flat 30% tax on the gain derived from the sale, which tax may be offset by certain U.S. source capital losses (even though you are not considered a resident of the United States); provided that you have
timely filed U.S. federal income tax returns with respect to such losses; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">our common stock constitutes a “United States real property interest” by reason of our status as a “United States real property holding corporation” for U.S. federal income tax purposes, a USRPHC, at
any time within the shorter of the five-year period preceding the disposition or your holding period for our common stock. We believe that we are not currently and will not become a USRPHC. However, because the determination of whether we are a
USRPHC depends on the fair market value of our U.S. real property relative to the fair market value of our other business assets, there can be no assurance that we will not become a USRPHC in the future. Even if we become a USRPHC, however, as long
as our common stock is regularly traded on an established securities market, such common stock will be treated as United States real property interests only if you actually or constructively hold more than five percent of such regularly traded
common stock at any time during the applicable period that is specified in the Code. If we are a USRPHC and either our common stock is not regularly traded on an established securities market or you hold, or are treated as holding, more than 5% of
our outstanding common stock, directly or indirectly, during the applicable testing period, you will generally be taxed on any gain in the same manner as gain that is effectively connected with the conduct of a U.S. trade or business, except that
the branch profits tax generally will not apply. If we are a USRPHC and our common stock is not regularly traded on an established securities market, your proceeds received on the disposition of shares will also generally be subject to withholding
at a rate of 15%. You are encouraged to consult your own tax advisor regarding the possible consequences to you if we are, or were to become, a USRPHC. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Federal Estate Tax </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock
held (or treated as held) by an individual who is neither a U.S. citizen nor a U.S. resident (as defined for estate tax purposes) at the time of death will be included in such holder’s gross estate for U.S. federal estate tax purposes, unless
an applicable estate tax treaty provides otherwise, and therefore may be subject to U.S. federal estate tax. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Backup Withholding and Information
Reporting </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, we must report annually to the IRS the amount of any distributions (whether or not they constitute dividends for
U.S. federal income tax purposes) paid to you, your name and address, and the amount of tax withheld, if any. A similar report will be sent to you. Pursuant to applicable income tax treaties or other agreements, the IRS may make these reports
available to tax authorities in your country of residence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments of dividends or of proceeds on the disposition of stock made to you
may be subject to additional information reporting and backup withholding at a current rate of 28% unless you establish an exemption, for </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
example by properly certifying your non-U.S. status on an IRS Form W-8BEN, IRS Form W-8BEN-E or another appropriate version of IRS Form W-8. Notwithstanding the foregoing, backup withholding and
information reporting may apply if either we or our paying agent has actual knowledge, or reason to know, that you are a U.S. person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Backup withholding is not an additional tax; rather, the U.S. income tax liability of persons subject to backup withholding will be reduced by
the amount of tax withheld. If withholding results in an overpayment of taxes, a refund or credit may generally be obtained from the IRS, provided that the required information is furnished to the IRS in a timely manner. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legislation and Guidance Affecting Taxation of Our Common Stock Held By or Through Foreign Entities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legislation and administrative guidance (referred to as the Foreign Account Tax Compliance Act or “FATCA”) generally imposes a U.S.
federal withholding tax of 30% on any dividends paid and, after December 31, 2018, the proceeds of a sale of our common stock paid to (i) a “foreign financial institution” (as specially defined under these rules), whether such
foreign financial institution is the beneficial owner or an intermediary, unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial
information regarding U.S. account holders of such institution (which includes certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or (ii) a non-financial foreign
entity, whether such non-financial foreign entity is the beneficial owner or an intermediary, unless such entity provides a certification that the beneficial owner of the payment does not have any substantial U.S. owners or provides the withholding
agent with a certification identifying the direct and indirect U.S. owners of the entity. Under certain circumstances, a non-U.S. holder might be eligible for refunds or credits of such taxes from the IRS, provided that the required information is
furnished to the IRS in a timely manner. In certain cases, the relevant foreign financial institution or non-financial foreign entity may qualify for an exemption from, or be deemed to be in compliance with, these rules. If the country in which the
payee is resident has entered into an “intergovernmental agreement” with the United States regarding FATCA, the payee may be permitted to report to that country instead of the United States, and the intergovernmental agreement may
otherwise modify the requirements described in this paragraph. Prospective investors are encouraged to consult with their own tax advisors regarding the possible implications of this legislation on their investment in our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>The preceding discussion of U.S. federal tax considerations is for general information only. It is not tax advice. Each prospective
investor should consult its own tax advisor regarding the particular U.S. federal, state, local and non-U.S. tax consequences of purchasing, holding and disposing of our common stock, including the consequences of any proposed change in applicable
laws. </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_10"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement, dated June , 2017, between us and Cantor
Fitzgerald & Co., as the sole book-running manager of this offering, we have agreed to sell to Cantor Fitzgerald & Co., and Cantor Fitzgerald & Co. has agreed to purchase from us, the shares of common stock offered by this
prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriting agreement provides that the obligations of Cantor Fitzgerald & Co. are subject to certain
conditions precedent such as the receipt by Cantor Fitzgerald & Co. of officers’ certificates and legal opinions and approval of certain legal matters by its counsel. The underwriting agreement provides that Cantor
Fitzgerald & Co. will purchase all of the shares of common stock if any of them are purchased. We have agreed to indemnify Cantor Fitzgerald & Co. and certain of its controlling persons against certain liabilities, including
liabilities under the Securities Act, and to contribute to payments that Cantor Fitzgerald & Co. may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald & Co. is offering the shares of common stock subject to its acceptance of the shares of common stock from us and
subject to prior sale. Cantor Fitzgerald & Co. reserves the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
have granted to Cantor Fitzgerald & Co. an option, exercisable for 30 days from the date of this prospectus supplement, to purchase, from time to time, in whole or in part, up to an aggregate of
shares from us at the public offering price set forth on the cover page of this prospectus supplement, less underwriting discounts and commissions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commission and Expenses </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cantor
Fitzgerald & Co. has advised us that it proposes to offer the shares of common stock to the public at the public offering price set forth on the cover page of this prospectus supplement and to certain dealers, which may include the
underwriters, at that price less a concession not in excess of $ per share of common stock. Cantor Fitzgerald & Co. may allow, and certain dealers may reallow, a discount from the
concession not in excess of $ per share of common stock to certain brokers and dealers. After the offering, Cantor Fitzgerald & Co. may change the offering price and other selling terms.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the public offering price, the underwriting discounts and commissions that we are to pay Cantor
Fitzgerald & Co. and the proceeds, before expenses, to us in connection with this offering. Such amounts are shown assuming both no exercise and full exercise of Cantor Fitzgerald & Co.’s option to purchase additional shares.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">
<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share</B></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>Option to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With<BR>Option to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>Option to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With<BR>Option to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom"> </TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> </TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> </TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> </TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> </TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions</P></TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and
commissions referred to above, will be approximately $370,000. We have also agreed to reimburse the underwriters for up to $15,000 for their FINRA counsels’ fees and expenses, which reimbursed fee is deemed underwriting compensation for this
offering by FINRA. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The NASDAQ Global Select Market under the trading symbol “PACB.” </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales of Similar Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, our
executive officers and our directors have agreed, subject to certain specified exceptions, not to directly or indirectly, for a period of 90 days after the date of the underwriting agreement: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open “put equivalent position” within the meaning of Rule 16a-l(h) under the Securities Exchange Act
of 1934, as amended, or otherwise dispose of, any shares of common stock, options or warrants to acquire shares of common stock, or securities exchangeable or exercisable for or convertible into shares of common stock currently or hereafter owned
either of record or beneficially; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">enter into any swap, hedge or other agreement or transaction that transfers, in whole or in part, the economic consequence of ownership of common stock, or securities exchangeable or exercisable for or convertible into
shares of common stock; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">publicly announce an intention to do any of the foregoing for a period of 90 days after the date of this prospectus supplement without the prior written consent of Cantor Fitzgerald & Co. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we and each such person agrees that, without the prior written consent of Cantor Fitzgerald & Co., we or such other
person will not, during the restricted period, make any demand for, or exercise any right with respect to, the registration of any shares of common stock or any security convertible into or exercisable or exchangeable for common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald & Co. may, in its sole discretion and at any time or from time to time before the termination of the 90-day period
release all or any portion of the securities subject to lock-up agreements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stabilization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriter has advised us that it, pursuant to Regulation M under the Securities Exchange Act of 1934, as amended, may engage in short
sale transactions, stabilizing transactions, syndicate covering transactions or the imposition of penalty bids in connection with this offering. These activities may have the effect of stabilizing or maintaining the market price of the common stock
at a level above that which might otherwise prevail in the open market. Establishing short sales positions may involve either “covered” short sales or “naked” short sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">“Covered” short sales are sales made in an amount not greater than the underwriter’s option to purchase additional shares of
our common stock in this offering. The underwriter may close out any covered short position by either exercising its option to purchase additional shares of our common stock or purchasing shares of our common stock in the open market. In determining
the source of shares to close out the covered short position, the underwriter will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which it may purchase shares through the
option to purchase additional shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">“Naked” short sales are sales in excess of the option to purchase additional shares of
our common stock. The underwriter must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriter is concerned that there may be downward pressure on the price
of the shares of our common stock in the open market after pricing that could adversely affect investors who purchase in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A
stabilizing bid is a bid for the purchase of shares of common stock on behalf of the underwriter for the purpose of fixing or maintaining the price of the common stock. A syndicate covering transaction is the bid for or the purchase of shares of
common stock on behalf of the underwriter to reduce a short position incurred by the </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
underwriter in connection with the offering. Similar to other purchase transactions, the underwriter’s purchases to cover the syndicate short sales may have the effect of raising or
maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. A
penalty bid is an arrangement permitting the underwriter to reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering if the common stock originally sold by such syndicate member are purchased in a
syndicate covering transaction and therefore have not been effectively placed by such syndicate member. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the underwriter
make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common stock. The underwriter is not obligated to engage in these activities and, if commenced,
may end any of these activities at any time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Passive Market Making </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriter may also engage in passive market making transactions in our common stock on the NASDAQ in accordance with Rule 103 of
Regulation M during a period before the commencement of offers or sales of shares of our common stock in this offering and extending through the completion of distribution. A passive market maker must display its bid at a price not in excess of
the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker’s bid, that bid must then be lowered when specified purchase limits are exceeded. Passive market making may cause the
price of our common stock to be higher than the price that otherwise would exist in the open market in the absence of those transactions. The underwriter is not required to engage in passive market making and, if commenced, may end passive market
making activities at any time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus in electronic format may be made available by e-mail or on the web sites or through online services maintained by one or more of
the underwriters, selling group members (if any) or their affiliates. The underwriter may agree with us to allocate a specific number of shares of common stock for sale to online brokerage account holders. Any such allocation for online
distributions will be made by the underwriter on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriter’s web site and any information contained in any other web site maintained
by the underwriter is not part of this prospectus supplement, has not been approved and/or endorsed by us or the underwriter and should not be relied upon by investors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Activities and Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald & Co. and certain of its affiliates are full service financial institutions engaged in a wide range of activities
for their own accounts and the accounts of customers, which may include, among other things, corporate finance, mergers and acquisitions, merchant banking, equity and fixed income sales, trading and research, derivatives, foreign exchange, futures,
asset management, custody, clearance and securities lending. Cantor Fitzgerald & Co. and certain of its affiliates have, from time to time, performed, and may in the future perform, various investment banking and financial advisory services
for us and our affiliates, for which it received or will receive customary fees and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the ordinary course of its
business, Cantor Fitzgerald & Co. and its affiliates may, directly or indirectly, hold long or short positions, trade and otherwise conduct such activities in or with respect to debt or equity securities and/or bank debt of, and/or
derivative products. Such investment and securities activities may involve our securities and instruments. Cantor Fitzgerald & Co. and its affiliates may also make investment recommendations or publish or express independent research views
in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions in such securities and instruments. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cantor Fitzgerald & Co. is the agent under our Sales Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stamp Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you purchase shares of
common stock offered in this prospectus supplement, you may be required to pay stamp taxes and other charges under the laws and practices of the country of purchase, in addition to the offering price listed on the cover page of this prospectus
supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Investors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Australia
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is not a disclosure document for the purposes of Australia’s Corporations Act 2001 (Cth) of Australia, or
Corporations Act, has not been lodged with the Australian Securities & Investments Commission and is only directed to the categories of exempt persons set out below. Accordingly, if you receive this prospectus in Australia: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You confirm and warrant that you are either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">a “sophisticated investor” under section 708(8)(a) or (b) of the Corporations Act; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">a “sophisticated investor” under section 708(8)(c) or (d) of the Corporations Act and that you have provided an accountant’s certificate to the company which complies with the requirements of section
708(8)(c)(i) or (ii) of the Corporations Act and related regulations before the offer has been made; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">a “professional investor” within the meaning of section 708(11)(a) or (b) of the Corporations Act. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor or professional investor under the
Corporations Act any offer made to you under this prospectus is void and incapable of acceptance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You warrant and agree that you will not
offer any of the shares issued to you pursuant to this prospectus for resale in Australia within 12 months of those securities being issued unless any such resale offer is exempt from the requirement to issue a disclosure document under section 708
of the Corporations Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>European Economic Area </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each member state of the European Economic Area which has implemented the Prospectus Directive, each referred to herein as a
Relevant Member State, with effect from and including the date on which the Prospectus Directive is implemented in that Relevant Member State, referred to herein as the Relevant Implementation Date, no offer of any securities which are the subject
of the offering contemplated by this prospectus has been or will be made to the public in that Relevant Member State other than any offer where a prospectus has been or will be published in relation to such securities that has been approved by the
competent authority in that Relevant Member State or, where appropriate, approved in another Relevant Member State and notified to the relevant competent authority in that Relevant Member State in accordance with the Prospectus Directive, except
that with effect from and including the Relevant Implementation Date, an offer of such securities may be made to the public in that Relevant Member State: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a “qualified investor” as defined in the Prospectus Directive; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus
Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representatives of the underwriters for any such offer; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided that no such offer of securities shall require the Company or any of the underwriters to publish a
prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an “offer to the public” in relation to any securities in any Relevant Member
State means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to purchase or subscribe the securities, as the same may be varied
in that Relevant Member State by any measure implementing the Prospectus Directive in that Relevant Member State and the expression “Prospectus Directive” means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending
Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State and the expression “2010 PD Amending Directive” means Directive 2010/73/EU. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hong Kong </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No securities have been
offered or sold, and no securities may be offered or sold, in Hong Kong, by means of any document, other than to persons whose ordinary business is to buy or sell shares or debentures, whether as principal or agent; or to “professional
investors” as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or in other circumstances which do not result in the document being a “prospectus” as defined in the
Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap.32) of Hong Kong. No document, invitation or advertisement relating to the securities has been
issued or may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public of
Hong Kong (except if permitted under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside Hong Kong or only to “professional investors” as defined
in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has not been
registered with the Registrar of Companies in Hong Kong. Accordingly, this prospectus may not be issued, circulated or distributed in Hong Kong, and the securities may not be offered for subscription to members of the public in Hong Kong. Each
person acquiring the securities will be required, and is deemed by the acquisition of the securities, to confirm that he is aware of the restriction on offers of the securities described in this prospectus and the relevant offering documents and
that he is not acquiring, and has not been offered any securities in circumstances that contravene any such restrictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Japan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering has not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948 of
Japan, as amended), or FIEL, and the Initial Purchaser will not offer or sell any securities, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means, unless otherwise provided herein,
any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to a resident of Japan,
except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the FIEL and any other applicable laws, regulations and ministerial guidelines of Japan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Singapore </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has not
been and will not be lodged or registered with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or the invitation for subscription or purchase of the
securities may not be issued, circulated or distributed, nor may the securities be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to the public or any member of the public in
Singapore other than (i) to an institutional investor </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
under Section 274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA, (ii) to a relevant person as defined under Section 275(2), or any person pursuant to
Section 275(1A) of the SFA, and in accordance with the conditions, specified in Section 275 of the SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of any other applicable provision of the SFA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the securities are subscribed or purchased under Section 275 of the SFA by a relevant person which is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">a corporation (which is not an accredited investor as defined under Section 4A of the SFA) the sole business of which is to hold investments and the entire share capital of which is owned by one or more
individuals, each of whom is an accredited investor; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary is an accredited investor, </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">shares, debentures and units of shares and debentures of that corporation or the beneficiaries’ rights and interest in that trust shall not be
transferable for six months after that corporation or that trust has acquired the Offer Shares under Section 275 of the SFA except: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor under Section 274 of the SFA or to a relevant person defined in Section 275(2) of the SFA, or to any person pursuant to an offer that is made on terms that such shares, debentures
and units of shares and debentures of that corporation or such rights and interest in that trust are acquired at a consideration of not less than $200,000 (or its equivalent in a foreign currency) for each transaction, whether such amount is to be
paid for in cash or by exchange of securities or other assets, and further for corporations, in accordance with the conditions, specified in Section 275 of the SFA; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">where no consideration is given for the transfer; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">where the transfer is by operation of law. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Switzerland </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock
exchange or regulated trading facility in Switzerland. This prospectus has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards
for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this prospectus nor any other offering or marketing material relating to the
securities or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither this prospectus nor
any other offering or marketing material relating to the offering, the Company or the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this prospectus will not be filed with, and the offer of
securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, or FINMA, and the offer of securities has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The
investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Israel </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This document does not
constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with or approved by the Israel Securities Authority. In the State of Israel, this document is being distributed only to, and is
directed only at, and any offer of the shares is directed only at, investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies,
banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
excess of NIS 50 million and “qualified individuals”, each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors (in
each case purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors will be required to submit written confirmation that they fall within
the scope of the Addendum, are aware of the meaning of same and agree to it. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>United Kingdom </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is only being distributed to, and is only directed at, persons in the United Kingdom that are qualified investors (as defined
in the Prospectus Directive) that are also (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, referred to herein as the Order, and/or
(ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order and other persons to whom it may lawfully be communicated. Each such person is referred to herein as a Relevant Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and its contents are confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by
recipients to any other persons in the United Kingdom. Any person in the United Kingdom that is not a Relevant Person should not act or rely on this document or any of its contents. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain legal matters with respect to the validity of our shares of common stock offered by this prospectus supplement will be passed upon for
us by Wilson Sonsini Goodrich & Rosati, Professional Corporation, Palo Alto, California. Certain legal matters will be passed upon for the underwriters by Cooley LLP, New York, New York. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_12"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ernst & Young LLP, an independent registered public accounting firm, has audited our consolidated financial statements included in
our Annual Report on Form 10-K for the year ended December 31, 2016, and the effectiveness of our internal control over financial reporting as of December 31, 2016, as set forth in their reports, which are incorporated by reference in this
prospectus supplement and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on the reports of Ernst & Young LLP, given the authority of said firm as experts in accounting and
auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_13"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form S-3 under the Securities Act with respect to the common stock offered by this
prospectus supplement and the accompanying prospectus. This prospectus supplement and the accompanying prospectus, filed as part of the registration statement, do not contain all the information set forth in the registration statement and its
exhibits and schedules, portions of which have been omitted as permitted by the rules and regulations of the SEC. For further information about us, we refer you to the registration statement and to its exhibits and schedules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and other reports, proxy statements and other information with the SEC. Our SEC filings are available to the public
over the Internet at the SEC’s website at www.sec.gov. You may also read and copy any document we file at the SEC’s Public Reference Room at 100 F Street, NE, Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further
information on the Public Reference Room. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, including any amendments to those reports, and other information that we file with or furnish to the
SEC pursuant to Section 13(a) or 15(d) of the Exchange Act can also be accessed free of charge through the Internet. These filings will be available as soon as reasonably practicable after we electronically file such material with, or furnish
it to, the SEC. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_14"></A>INFORMATION INCORPORATED BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference into this prospectus supplement and the accompanying prospectus certain information we file with
it, which means that we can disclose important information by referring you to those documents. The information incorporated by reference is considered to be a part of this prospectus supplement and the accompanying prospectus, and information that
we file later with the SEC will automatically update and supersede information contained in this prospectus supplement and the accompanying prospectus. We incorporate by reference the documents listed below that we have previously filed with the SEC
(excluding any portions of any Form 8-K that are not deemed “filed” pursuant to the General Instructions of Form 8-K): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, including the information specifically incorporated by reference into the Form 10-K from our definitive proxy statement for our 2017
Annual Meeting of Stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">our Quarterly Report on Form 10-Q for the quarter ended March 31, 2017; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">our Current Reports on Form 8-K filed with SEC on February 2, 2017, April 26, 2017, May 25, 2017 and June 14, 2017 (in each case, not including any information furnished under Items 2.02 or 7.01
of Form 8-K, including the related exhibits, which information is not incorporated by reference herein, unless such information under Item 2.02 is explicitly deemed “filed” for purposes of the Exchange Act); and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"> </TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the description of our common stock contained in our Registration Statement on Form 8-A as filed with the SEC on October 6, 2010, including any amendment or report filed for the purpose of updating such
description. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference into this prospectus supplement and the accompanying prospectus additional
documents that we may file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the completion or termination of the offering, but excluding any information deemed furnished and not filed with the SEC. Any
statements contained in a previously filed document incorporated by reference into this prospectus supplement and the accompanying prospectus is deemed to be modified or superseded for purposes of this prospectus supplement and the accompanying
prospectus to the extent that a statement contained in this prospectus supplement and the accompanying prospectus, or in a subsequently filed document also incorporated by reference herein and therein, modifies or supersedes that statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide to each person to whom this prospectus supplement and the accompanying prospectus is delivered, upon written or oral request,
at no cost to the requester, a copy of any and all of the information that is incorporated by reference in this prospectus supplement and the accompanying prospectus. Requests for such documents should be directed to: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Pacific Biosciences of California, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1305 O’Brien Drive </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Menlo
Park, California 94025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(650) 521-8000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Investor Relations </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">
<IMG SRC="g402129g53x69.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$150,000,000 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Pacific Biosciences of California, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>By this prospectus, Pacific Biosciences may offer, from time to time: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%"> </P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="38%"> </TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top"><B>Common stock</B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="38%"> </TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>•</B></TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top"><B>Preferred stock </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="38%"> </TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>•</B></TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top"><B>Depositary Shares </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="38%"> </TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>•</B></TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top"><B>Warrants </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="38%"> </TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>•</B></TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top"><B>Debt securities </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:14pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="38%"> </TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>•</B></TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top"><B>Units </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pacific Biosciences of California, Inc. a Delaware corporation (“Pacific
Biosciences” or “PacBio”) may offer and sell from time to time, in one or more series or issuances and on terms that Pacific Biosciences will determine at the time of the offering, any combination of the securities described in this
prospectus, up to an aggregate amount of $150,000,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide specific terms of any offering in a supplement to this prospectus.
Any prospectus supplement may also add, update, or change information contained in this prospectus. You should carefully read this prospectus and the applicable prospectus supplement as well as the documents incorporated or deemed to be incorporated
by reference in this prospectus before you purchase any of the securities offered hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These securities may be offered and sold in the
same offering or in separate offerings; to or through underwriters, dealers, and agents; or directly to purchasers. The names of any underwriters, dealers, or agents involved in the sale of our securities, their compensation and any over-allotment
options held by them will be described in the applicable prospectus supplement. For a more complete description of the plan of distribution of these securities, see the section entitled “Plan of Distribution” beginning on page 28 of this
prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market under the symbol “PACB.” We will provide information
in any applicable prospectus supplement regarding any listing of securities other than shares of our common stock on any securities exchange. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%"> </P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>INVESTING IN
OUR SECURITIES INVOLVES SIGNIFICANT RISKS. SEE “<A HREF="#suprom402129_17">RISK FACTORS</A>” BEGINNING ON PAGE 4 OF THIS PROSPECTUS AND IN THE APPLICABLE PROSPECTUS SUPPLEMENT BEFORE INVESTING IN ANY SECURITIES. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR
PASSED UPON THE ADEQUACY OR ACCURACY OF THIS PROSPECTUS. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%"> </P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is November 21, 2014 </B></P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">
<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_16">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_17">Risk Factors</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_18">Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_19">Ratio of Earnings To Fixed Charges</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_20">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_21">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_22">Description of the Depositary Shares</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_23">Description of the Warrants</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_24">Description of the Debt Securities</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_25">Description of the Units</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_26">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_27">Legal Matters</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_28">Experts</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_29">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#suprom402129_30">Information Incorporated by Reference</A></P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom"></TD></TR>
</TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-i- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form S-3 that we filed with the United States Securities and Exchange Commission, or
the SEC, using a “shelf” registration process. Under this shelf process, we may, from time to time, sell any combination of the securities described in this prospectus in one or more offerings up to a total amount of $150,000,000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus provides you with a general description of the securities we may offer. Each time we sell securities, we will provide a
prospectus supplement that will contain specific information about the terms of that offering. The prospectus supplement may also add to, update or change information contained in the prospectus and, accordingly, to the extent inconsistent,
information in this prospectus is superseded by the information in the prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The prospectus supplement to be attached to
the front of this prospectus may describe, as applicable: the terms of the securities offered; the initial public offering price; the price paid for the securities; net proceeds; and the other specific terms related to the offering of the
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">You should only rely on the information contained or incorporated by reference in this prospectus and any prospectus
supplement or issuer free writing prospectus relating to a particular offering. No person has been authorized to give any information or make any representations in connection with this offering other than those contained or incorporated by
reference in this prospectus, any accompanying prospectus supplement and any related issuer free writing prospectus in connection with the offering described herein and therein, and, if given or made, such information or representations must not be
relied upon as having been authorized by us. Neither this prospectus nor any prospectus supplement nor any related issuer free writing prospectus shall constitute an offer to sell or a solicitation of an offer to buy offered securities in any
jurisdiction in which it is unlawful for such person to make such an offering or solicitation. This prospectus does not contain all of the information included in the registration statement. For a more complete understanding of the offering of the
securities, you should refer to the registration statement, including its exhibits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">You should read the entire prospectus and any
prospectus supplement and any related issuer free writing prospectus, as well as the documents incorporated by reference into this prospectus or any prospectus supplement or any related issuer free writing prospectus, before making an investment
decision. Neither the delivery of this prospectus or any prospectus supplement or any issuer free writing prospectus nor any sale made hereunder shall under any circumstances imply that the information contained or incorporated by reference herein
or in any prospectus supplement or issuer free writing prospectus is correct as of any date subsequent to the date hereof or of such prospectus supplement or issuer free writing prospectus, as applicable. You should assume that the information
appearing in this prospectus, any prospectus supplement or any document incorporated by reference is accurate only as of the date of the applicable documents, regardless of the time of delivery of this prospectus or any sale of securities. Our
business, financial condition, results of operations and prospects may have changed since that date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The names “Pacific
Biosciences,” “PacBio,” “SMRT,” “SMRTbell” and our logo are our trademarks. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-1- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_16"></A>Prospectus Summary </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><I>This summary description about us and our business highlights selected information contained elsewhere in this prospectus or incorporated
in this prospectus by reference. This summary does not contain all of the information you should consider before buying securities in this offering. You should carefully read this entire prospectus and any applicable prospectus supplement, including
each of the documents incorporated herein or therein by reference, before making an investment decision. As used in this prospectus, “we,” “us,” “Pacific Biosciences,” “PacBio,” “the Company” and
“our” refer to Pacific Biosciences of California, Inc., a Delaware corporation. </I></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pacific Biosciences of California, Inc.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We develop,
manufacture and market an integrated platform for high resolution genetic analysis. We have developed a technology to study the synthesis, composition, structure, and regulation of DNA. Combining advances in nanofabrication, biochemistry, molecular
biology, surface chemistry and optics, we created a technology platform using our proprietary single molecule, real-time, or SMRT, technology. Our SMRT technology uses the natural processing power of enzymes, combined with specially designed
reagents and detection systems, to record individual biochemical events as they occur. The ability to observe single molecule events in real time provides the scientific community with an advanced tool for investigating basic biochemical processes
such as DNA synthesis. Our SMRT technology has the potential to advance scientific understanding by providing a window into biological processes that has not previously been open. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our initial focus is to offer our SMRT technology to the DNA sequencing market where we have developed a third generation sequencing platform,
the PacBio RS II sequencing system. The PacBio RS II is an instrument that uses our proprietary consumables, including our SMRT Cells and reagent kits that are used to prepare and sequence DNA samples. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PacBio RS II maintains many of the key attributes of first and second generation sequencing technologies while solving many of their
inherent limitations, including short read lengths, limited flexibility, long time to result, complex sample preparation and risk of amplification bias. Our system provides long read lengths, flexibility in experimental design, fast time
to result, and avoidance of amplification bias. Our system is designed to be integrated into existing laboratory workflows and information systems. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pacific
Biosciences of California, Inc., formerly Nanofluidics, Inc. was incorporated in the State of Delaware in 2000. Our executive offices are located at 1380 Willow Road, Menlo Park, California 94025, and our telephone number is (650) 521-8000. We
maintain a website at www.pacificbiosciences.com where general information about us is available. Our website, and the information contained therein, is not a part of this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Securities We May Offer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may
offer up to $150,000,000 of common stock, preferred stock, depositary shares, warrants, debt securities and/or units in one or more offerings and in any combination. This prospectus provides you with a general description of the securities we may
offer. A prospectus supplement, which we will provide each time we offer securities, will describe the specific amounts, prices and terms of the securities we determine to offer. </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt"> </P></div><br clear="All"></div><br clear="All">
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Common Stock </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may offer shares of our common stock, par value $0.001 per share, either alone or underlying other registered securities convertible or
exercisable into our common stock. Each holder of our common stock is entitled to one vote for each share on all matters to be voted upon by the stockholders. Holders of our common stock are entitled to receive ratably the dividends, if any, as may
be declared from time to time by our board of directors out of funds legally available therefor. If there is a liquidation, dissolution or winding up of our company, holders of our common stock would be entitled to share in our assets remaining
after the payment of liabilities and any preferential rights of any outstanding preferred stock. The holders of common stock have no preemptive rights. Currently, we do not pay a dividend and do not anticipate paying cash dividends in the
foreseeable future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Preferred Stock and Depositary Shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the terms of our amended and restated certificate of incorporation, our board of directors is authorized to issue shares of preferred
stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges
and liquidation preferences, of each series of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may also issue fractional shares of preferred stock that will be
represented by depositary shares and depositary receipts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each series of preferred stock, depositary shares or depositary receipts, if
issued, will be more fully described in the particular prospectus supplement that will accompany this prospectus, including redemption provisions, rights in the event of our liquidation, dissolution or winding up, voting rights and rights to convert
into common stock. We do not have any shares of our preferred stock, depositary shares or depositary receipts presently outstanding. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Warrants </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may issue
warrants for the purchase of common stock, preferred stock or debt securities. We may issue warrants independently or together with other securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Debt Securities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may
offer secured or unsecured obligations in the form of one or more series of senior or subordinated debt. The senior debt securities and the subordinated debt securities are together referred to in this prospectus as the “debt securities.”
The subordinated debt securities generally will be entitled to payment only after payment of our senior debt. Senior debt generally includes all debt for money borrowed by us, except debt that is stated in the instrument governing the terms of that
debt to be not senior to, or to have the same rank in right of payment as, or to be expressly junior to, the subordinated debt securities. We may issue debt securities that are convertible into shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The senior and subordinated debt securities will be issued under separate indentures between us and a trustee. We have summarized the general
features of the debt securities to be governed by the indentures. These indentures have been filed as exhibits to the registration statement of which this prospectus forms a part. We encourage you to read these indentures. Instructions on how you
can get copies of these documents are provided under the heading “Where You Can Find More Information.” </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Units </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may issue units comprised of one or more of the other classes of securities issued by us as described in this prospectus in any combination.
Each unit will be issued so that the holder of the unit is also the holder of each security included in the unit. </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt"> </P></div><br clear="All"></div><br clear="All">
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_17"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">An investment in our securities involves a high degree of risk. The prospectus supplement applicable to each offering of our securities will
contain a discussion of the risks applicable to an investment in our securities. Prior to making a decision about investing in our securities, you should carefully consider the specific factors discussed under the heading “Risk Factors” in
the applicable prospectus supplement, together with all of the other information contained or incorporated by reference in the prospectus supplement or appearing or incorporated by reference in this prospectus. You should also consider the risks,
uncertainties and assumptions discussed under Item 1A, “Risk Factors,” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013 and any updates described in our Quarterly Reports on Form 10-Q, all of which
are incorporated herein by reference, and may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future and any prospectus supplement related to a particular offering. The risks and uncertainties we
have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. The occurrence of any of these known or unknown risks might cause you to
lose all or part of your investment in the offered securities. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_18"></A>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus, each prospectus supplement and the information incorporated by reference in this prospectus and each prospectus supplement
contain certain statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words “anticipate,”
“could,” “expect,” “believe,” “goal,” “plan,” “intend,” “estimate,” “may,” “seek,” “potential,” “predict,” “project,”
“should,” “would,” “will,” and similar expressions and variations thereof are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. Those statements appear in
this prospectus, any accompanying prospectus supplement and the documents incorporated herein and therein by reference, particularly in the sections entitled “Prospectus Summary,” “Risk Factors,” “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” and “Business,” and include statements regarding the intent, belief or current expectations of the company and management that are subject to known and unknown
risks, uncertainties and assumptions and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or
contribute to such differences include, but are not limited to those discussed in the section titled “Risk Factors” set forth above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus, any prospectus supplement and the information incorporated by reference in this prospectus and any prospectus supplement also
contain statements that are based on management’s current expectations and beliefs, including estimates and projections about our company, industry, financial condition, results of operations and other matters. These statements are not
guarantees of future performance and are subject to numerous risks, uncertainties, and assumptions that are difficult to predict. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Because
forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely upon forward-looking statements as predictions of future events. The events and circumstances
reflected in the forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, including the securities laws of the
United States and the rules and regulations of the SEC, we do not plan to publicly update or revise any forward-looking statements contained herein after we distribute this prospectus, whether as a result of any new information, future events or
otherwise. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-4- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RATIO OF EARNINGS TO FIXED CHARGES<A NAME="suprom402129_19"></A> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our earnings are inadequate to cover fixed charges. The following table sets forth the ratio of earnings to fixed charges for each of the
years ended December 31, 2013, 2012, 2011, 2010 and 2009 and for the nine months ended September 30, 2014 and 2013. The following should be read in conjunction with our consolidated financial statements, including the notes thereto, and
the other financial information included or incorporated by reference herein. See Exhibit 12.1 hereto for additional detail regarding the computation of the deficiency of earnings to cover fixed charges. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">
<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended<BR>September 30,</B></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fiscal Year Ended December 31,</B></TD>
<TD VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2010</B></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2009</B></TD>
<TD VALIGN="bottom"> </TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B></B><I>(dollars in thousands)</I><B></B></TD>
<TD VALIGN="bottom"> </TD>
<TD COLSPAN="2" VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD COLSPAN="2" VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD COLSPAN="2" VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD COLSPAN="2" VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD COLSPAN="2" VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD COLSPAN="6" VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ratio of earnings to fixed charges (1)</P></TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom"> </TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom"> </TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">For the purpose of calculating such ratios, “earnings” consist of income from continuing operations before income taxes plus fixed charges and “fixed charges” consist of interest expense (net of
capitalized portion), capitalized interest, amortization of debt discount and the portion of rental expense representative of interest expense. Earnings were inadequate to cover the fixed charges by approximately $79,293, $94,465, $109,388, $140,166
and $87,703 for the years ended December 31, 2013, 2012, 2011, 2010 and 2009 and by approximately $47,185 and $62,062 for the nine months ended September 30, 2014 and September 30, 2013, respectively. </TD></TR></TABLE>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_20"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the prospectus supplement, we will use the net proceeds from the sale of securities offered by this prospectus
for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses and acquisitions of complementary products, technologies or businesses. The timing and amount of our actual expenditures will be based
on many factors, including cash flows from operations and the anticipated growth of our business. As a result, unless otherwise indicated in the prospectus supplement, our management will have broad discretion to allocate the net proceeds of the
offerings. Pending their ultimate use, we intend to invest the net proceeds in short-term, investment-grade, interest-bearing instruments. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-5- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_21"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following information describes our common stock and preferred stock, as well as certain provisions of our amended and restated
certificate of incorporation and bylaws. This description is only a summary. You should also refer to our certificate of incorporation and bylaws, which have been filed with the SEC as exhibits to our registration statement, of which this prospectus
forms a part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our
authorized capital stock consists of 1,000,000,000 shares of common stock with a $0.001 par value per share, and 50,000,000 shares of undesignated preferred stock with a $0.001 par value per share. Our board of directors may establish the rights and
preferences of the preferred stock from time to time. As of September 30, 2014, there were 70,976,000 shares of common stock issued and outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following is a summary of the material provisions of the common stock and preferred stock provided for in our amended and restated
certificate of incorporation and bylaws. For additional detail about our capital stock, please refer to our certificate of incorporation and bylaws, each as amended. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each holder of our common
stock is entitled to one vote for each share on all matters to be voted upon by the stockholders. Subject to any preferential rights of any outstanding preferred stock, holders of our common stock are entitled to receive ratably the dividends, if
any, as may be declared from time to time by the board of directors out of funds legally available therefor. We have never declared or paid any cash dividend on our capital stock and do not anticipate paying any cash dividends in the foreseeable
future. In the event of our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in our assets remaining after the payment of liabilities and any preferential rights of any outstanding preferred stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Holders of our common stock have no preemptive or conversion rights or other subscription rights, and there are no redemption or sinking
fund provisions applicable to the common stock. The outstanding shares of common stock are fully paid and non-assessable. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the
rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our common stock is
listed on the NASDAQ Global Select Market under the symbol “PACB.” The transfer agent and registrar for the common stock is Computershare Shareowner Services LLC. Its address is 480 Washington Boulevard, Jersey City, NJ 07310, and its
telephone number is 1-866-401-4874. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following description of preferred stock and the description of the terms of any particular series of preferred stock that we choose to
issue hereunder and that will be set forth in the related prospectus supplement are not complete. These descriptions are qualified in their entirety by reference to our amended and restated certificate of incorporation and the certificate of
designation relating to any series of preferred stock. The rights, preferences, privileges and restrictions of the preferred stock of each series will be fixed by the certificate of designation relating to that series. The prospectus supplement also
will contain a description of certain United States federal income tax consequences relating to the purchase and ownership of the series of preferred stock that is described in the prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the terms of our amended and restated certificate of incorporation, our board of directors is authorized to issue shares of preferred
stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-6- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. There are no restrictions presently on the repurchase or
redemption of any shares of our preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The prospectus supplement for a series of preferred stock will specify: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the maximum number of shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the designation of the shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the annual dividend rate, if any, whether the dividend rate is fixed or variable, the date or dates on which dividends will accrue, the dividend payment dates, and whether dividends will be cumulative;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the price and the terms and conditions for redemption, if any, including redemption at our option or at the option of the holders, including the time period for redemption, and any accumulated dividends or premiums;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the liquidation preference, if any, and any accumulated dividends upon the liquidation, dissolution or winding up of our affairs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">any sinking fund or similar provision, and, if so, the terms and provisions relating to the purpose and operation of the fund; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the terms and conditions, if any, for conversion or exchange of shares of any other class or classes of our capital stock or any series of any other class or classes, or of any other series of the same class, or any
other securities or assets, including the price or the rate of conversion or exchange and the method, if any, of adjustment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the voting rights; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">any or all other preferences and relative, participating, optional or other special rights, privileges or qualifications, limitations or restrictions. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The issuance of shares of preferred stock will affect, and may adversely affect, the rights of holders of common stock. It is not possible to
state the actual effect of the issuance of any shares of preferred stock on the rights of holders of common stock until our board of directors determines the specific rights attached to that preferred stock. The effects of issuing additional
preferred stock could include one or more of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">restricting dividends on the common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">diluting the voting power of the common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">impairing the liquidation rights of the common stock; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">delaying or preventing changes in control or management of our company. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Preferred stock will
be fully paid and nonassessable upon issuance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Effect of Certain Provisions of our Amended and Restated Certificate of Incorporation and Bylaws and
the Delaware Anti-Takeover Statute </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Some provisions of Delaware law and our amended and restated certificate of incorporation and
bylaws contain provisions that could make the following transactions more difficult: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">acquisition of us by means of a tender offer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">acquisition of us by means of a proxy contest or otherwise; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">removal of our incumbent officers and directors. </TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-7- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Those provisions, summarized below, are expected to discourage coercive takeover practices and
inadequate takeover bids and to promote stability in our management. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Amended and Restated Certificate of Incorporation and Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and our bylaws provide for the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top"><I>Undesignated Preferred Stock</I>. The ability to authorize undesignated preferred stock makes it possible for our board of directors to issue one or more series of preferred stock with voting or other rights or
preferences that could impede the success of any attempt to change control of our company. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top"><I>Stockholder Meetings</I>. Our bylaws provide that in general a special meeting of stockholders may be called only by our board of directors, its chairman or our president. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top"><I>Requirements for Advance Notification of Stockholder Nominations and Proposals</I>. Our bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election
as directors, other than nominations made by or at the direction of our board of directors or a committee of the board of directors. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top"><I>Board Classification</I>. Our board of directors is divided into three classes. The directors in each class are elected to serve for a three-year term, one class being elected each year by our stockholders. This
system of electing and removing directors may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the
directors. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top"><I>Limits on Ability of Stockholders to Act by Written Consent</I>. We have provided in our bylaws that our stockholders may not act by written consent. This limit on the ability of our stockholders to act by written
consent may lengthen the amount of time required to take stockholder actions. As a result, a holder controlling a majority of our capital stock would not be able to amend our bylaws or remove directors without holding a meeting of our stockholders
called in accordance with our bylaws. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top"><I>Amendment of Certificate of Incorporation and Bylaws. </I>The amendment of the above provisions of our amended and restated certificate of incorporation and bylaws requires approval by holders of at least two-thirds
of our outstanding capital stock entitled to vote generally in the election of directors. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Anti-Takeover
Statute </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are subject to the provisions of Section 203 of the Delaware General Corporation Law regulating corporate
takeovers. In general, Section 203 prohibits a publicly-held Delaware corporation from engaging, under certain circumstances, in a business combination with an interested stockholder for a period of three years following the date the person
became an interested stockholder unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, but not for determining the outstanding voting
stock owned by the interested stockholder, (i) shares owned by persons who are directors and also officers, and </P></TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-8- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%"> </TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
(ii) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a
tender or exchange offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">at or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by written
consent, by the affirmative vote of at least 66-2/3% of the outstanding voting stock which is not owned by the interested stockholder. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Generally, a business combination includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the
interested stockholder. An interested stockholder is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of a corporation’s
outstanding voting stock. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-9- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_22"></A>DESCRIPTION OF THE DEPOSITARY SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At our option, we may elect to
offer fractional shares of preferred stock, rather than full shares of preferred stock. If we do elect to offer fractional shares of preferred stock, we will issue receipts for depositary shares and each of these depositary shares will represent a
fraction of a share of a particular series of preferred stock, as specified in the applicable prospectus supplement. Each owner of a depositary share will be entitled, in proportion to the applicable fractional interest in shares of preferred stock
underlying that depositary share, to all rights and preferences of the preferred stock underlying that depositary share. These rights may include dividend, voting, redemption and liquidation rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The shares of preferred stock underlying the depositary shares will be deposited with a bank or trust company selected by us to act as
depositary, under a deposit agreement by and among us, the depositary and the holders of the depositary receipts. The depositary will be the transfer agent, registrar and dividend disbursing agent for the depositary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The depositary shares will be evidenced by depositary receipts issued pursuant to the depositary agreement. Holders of depositary receipts
agree to be bound by the deposit agreement, which requires holders to take certain actions such as filing proof of residence and paying certain charges. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The summary of terms of the depositary shares contained in this prospectus is not complete, and is subject to modification in any prospectus
supplement for any issuance of depositary shares. You should refer to the forms of the deposit agreement, our certificate of incorporation and the certificate of designation that are, or will be, filed with the SEC for the applicable series of
preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
depositary will distribute cash dividends or other cash distributions, if any, received in respect of the series of preferred stock underlying the depositary shares to the record holders of depositary receipts in proportion to the number of
depositary shares owned by those holders on the relevant record date. The relevant record date for depositary shares will be the same date as the record date for the preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event of a distribution other than in cash, the depositary will distribute property received by it to the record holders of depositary
receipts that are entitled to receive the distribution, unless the depositary determines that it is not feasible to make the distribution. If this occurs, the depositary, with our approval, may adopt another method for the distribution, including
selling the property and distributing the net proceeds to the holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidation preference </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If a series of preferred stock underlying the depositary shares has a liquidation preference, in the event of our voluntary or involuntary
liquidation, dissolution or winding up, holders of depositary shares will be entitled to receive the fraction of the liquidation preference accorded each share of the applicable series of preferred stock, as set forth in the applicable prospectus
supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If a series
of preferred stock underlying the depositary shares is subject to redemption, the depositary shares will be redeemed from the proceeds received by the depositary resulting from the redemption, in whole or in part, of the preferred stock held by the
depositary. Whenever we redeem any preferred stock held by the depositary, the depositary will redeem, as of the same redemption date, the number of depositary shares </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-10- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
representing the preferred stock so redeemed. The depositary will mail the notice of redemption to the record holders of the depositary receipts promptly upon receiving the notice from us and not
fewer than 20 or more than 60 days, unless otherwise provided in the applicable prospectus supplement, prior to the date fixed for redemption of the preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon receipt of notice of any
meeting at which the holders of preferred stock are entitled to vote, the depositary will mail the information contained in the notice of meeting to the record holders of the depositary receipts underlying the preferred stock. Each record holder of
those depositary receipts on the record date will be entitled to instruct the depositary as to the exercise of the voting rights pertaining to the amount of preferred stock underlying that holder’s depositary shares. The record date for the
depositary will be the same date as the record date for the preferred stock. The depositary will, to the extent practicable, vote the preferred stock underlying the depositary shares in accordance with these instructions. We will agree to take all
action that may be deemed necessary by the depositary in order to enable the depositary to vote the preferred stock in accordance with these instructions. The depositary will not vote the preferred stock to the extent that it does not receive
specific instructions from the holders of depositary receipts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Withdrawal of preferred stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Owners of depositary shares will be entitled to receive upon surrender of depositary receipts at the principal office of the depositary and
payment of any unpaid amount due to the depositary, the number of whole shares of preferred stock underlying their depositary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Partial shares of preferred stock will not be issued. Holders of preferred stock will not be entitled to deposit the shares under the deposit
agreement or to receive depositary receipts evidencing depositary shares for the preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment and termination of the deposit agreement
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The form of depositary receipt evidencing the depositary shares and any provision of the deposit agreement may be amended by agreement
between the depositary and us. However, any amendment which materially and adversely alters the rights of the holders of depositary shares, other than fee changes, will not be effective unless the amendment has been approved by at least a majority
of the outstanding depositary shares. The deposit agreement may be terminated by the depositary or us only if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">all outstanding depositary shares have been redeemed; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">there has been a final distribution of the preferred stock in connection with our dissolution and such distribution has been made to all the holders of depositary shares. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Charges of depositary </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will pay all
transfer and other taxes and governmental charges arising solely from the existence of the depositary arrangement. We will also pay charges of the depositary in connection with: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the initial deposit of the preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the initial issuance of the depositary shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">any redemption of the preferred stock; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">all withdrawals of preferred stock by owners of depositary shares. </TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-11- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Holders of depositary receipts will pay transfer, income and other taxes and governmental charges
and other specified charges as provided in the deposit agreement for their accounts. If these charges have not been paid, the depositary may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">refuse to transfer depositary shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">withhold dividends and distributions; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">sell the depositary shares evidenced by the depositary receipt. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Miscellaneous </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The depositary will forward to the holders of depositary receipts all reports and communications we deliver to the depositary that we are
required to furnish to the holders of the preferred stock. In addition, the depositary will make available for inspection by holders of depositary receipts at the principal office of the depositary, and at such other places as it may from time to
time deem advisable, any reports and communications we deliver to the depositary as the holder of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Neither the depositary
nor we will be liable if either the depositary or we are prevented or delayed by law or any circumstance beyond the control of either the depositary or us in performing our respective obligations under the deposit agreement. Our obligations and the
depositary’s obligations will be limited to the performance in good faith of our or the depositary’s respective duties under the deposit agreement. Neither the depositary nor we will be obligated to prosecute or defend any legal proceeding
in respect of any depositary shares or preferred stock unless satisfactory indemnity is furnished. The depositary and we may rely on: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">written advice of counsel or accountants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">information provided by holders of depositary receipts or other persons believed in good faith to be competent to give such information; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">documents believed to be genuine and to have been signed or presented by the proper party or parties. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Resignation and removal of depositary </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The depositary may resign at any time by delivering a notice to us. We may remove the depositary at any time. Any such resignation or removal
will take effect upon the appointment of a successor depositary and its acceptance of such appointment. The successor depositary must be appointed within 60 days after delivery of the notice for resignation or removal. The successor depositary must
be a bank and trust company having its principal office in the United States of America and having a combined capital and surplus of at least $100,000,000. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Federal income tax consequences </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Owners
of the depositary shares will be treated for U.S. federal income tax purposes as if they were owners of the preferred stock underlying the depositary shares. As a result, owners will be entitled to take into account for U.S. federal income tax
purposes and deductions to which they would be entitled if they were holders of such preferred stock. No gain or loss will be recognized for U.S. federal income tax purposes upon the withdrawal of preferred stock in exchange for depositary shares.
The tax basis of each share of preferred stock to an exchanging owner of depositary shares will, upon such exchange, be the same as the aggregate tax basis of the depositary shares exchanged. The holding period for preferred stock in the hands of an
exchanging owner of depositary shares will include the period during which such person owned such depositary shares. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-12- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_23"></A>DESCRIPTION OF THE WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may issue warrants for the
purchase of our debt securities, preferred stock or common stock, or any combination thereof. Warrants may be issued independently or together with our debt securities, preferred stock or common stock and may be attached to or separate from any
offered securities. Each series of warrants will be issued under a separate warrant agreement to be entered into between us and a bank or trust company, as warrant agent. The warrant agent will act solely as our agent in connection with the
warrants. The warrant agent will not have any obligation or relationship of agency or trust for or with any holders or beneficial owners of warrants. This summary of certain provisions of the warrants is not complete. For the terms of a particular
series of warrants, you should refer to the prospectus supplement for that series of warrants and the warrant agreement for that particular series. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Debt warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The prospectus supplement
relating to a particular issue of warrants to purchase debt securities will describe the terms of the debt warrants, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the title of the debt warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the offering price for the debt warrants, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the aggregate number of the debt warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the designation and terms of the debt securities, including any conversion rights, purchasable upon exercise of the debt warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">if applicable, the date from and after which the debt warrants and any debt securities issued with them will be separately transferable; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the principal amount of debt securities that may be purchased upon exercise of a debt warrant and the exercise price for the warrants, which may be payable in cash, securities or other property; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the dates on which the right to exercise the debt warrants will commence and expire; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">if applicable, the minimum or maximum amount of the debt warrants that may be exercised at any one time; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">whether the debt warrants represented by the debt warrant certificates or debt securities that may be issued upon exercise of the debt warrants will be issued in registered or bearer form; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">information with respect to book-entry procedures, if any; the currency or currency units in which the offering price, if any, and the exercise price are payable; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">if applicable, a discussion of material U.S. federal income tax considerations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the antidilution provisions of the debt warrants, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the redemption or call provisions, if any, applicable to the debt warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">any provisions with respect to the holder’s right to require us to repurchase the debt warrants upon a change in control or similar event; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">any additional terms of the debt warrants, including procedures, and limitations relating to the exchange, exercise and settlement of the debt warrants. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Debt warrant certificates will be exchangeable for new debt warrant certificates of different denominations. Debt warrants may be exercised at
the corporate trust office of the warrant agent or any other office indicated in the prospectus supplement. Prior to the exercise of their debt warrants, holders of debt </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-13- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
warrants will not have any of the rights of holders of the debt securities purchasable upon exercise and will not be entitled to payment of principal or any premium, if any, or interest on the
debt securities purchasable upon exercise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The prospectus supplement relating to a particular series of warrants to purchase our common stock or preferred stock will describe the terms
of the warrants, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the title of the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the offering price for the warrants, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the aggregate number of warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the designation and terms of the common stock or preferred stock that may be purchased upon exercise of the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each security; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">if applicable, the date from and after which the warrants and any securities issued with the warrants will be separately transferable; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the number of shares of common stock or preferred stock that may be purchased upon exercise of a warrant and the exercise price for the warrants; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the dates on which the right to exercise the warrants shall commence and expire; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the currency or currency units in which the offering price, if any, and the exercise price are payable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">if applicable, a discussion of material U.S. federal income tax considerations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the antidilution provisions of the warrants, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the redemption or call provisions, if any, applicable to the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">any provisions with respect to the holder’s right to require us to repurchase the warrants upon a change in control or similar event; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">any additional terms of the warrants, including procedures, and limitations relating to the exchange, exercise and settlement of the warrants. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Holders of equity warrants will not be entitled: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">to vote, consent or receive dividends; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">receive notice as stockholders with respect to any meeting of stockholders for the election of our directors or any other matter; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">exercise any rights as stockholders of us. </TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-14- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_24"></A>DESCRIPTION OF THE DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The debt securities may be either secured or unsecured and will either be our senior debt securities or our subordinated debt securities. The
debt securities will be issued under one or more separate indentures between us and a trustee to be specified in an accompanying prospectus supplement. Senior debt securities will be issued under a senior indenture and subordinated debt securities
will be issued under a subordinated indenture. Together, the senior indenture and the subordinated indenture are called indentures in this description. This prospectus, together with the applicable prospectus supplement, will describe the terms of a
particular series of debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following is a summary of selected provisions and definitions of the indentures and debt
securities to which any prospectus supplement may relate. The summary of selected provisions of the indentures and the debt securities appearing below is not complete and is subject to, and qualified entirely by reference to, all of the provisions
of the applicable indenture and certificates evidencing the applicable debt securities. For additional information, you should look at the applicable indenture and the certificate evidencing the applicable debt security that is filed as an exhibit
to the registration statement that includes the prospectus. In this description of the debt securities, the words “we,” “us,” or “our” refer only to Pacific Biosciences of California, Inc. and not to any of our
subsidiaries, unless we expressly state or the context otherwise requires. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following description sets forth selected general terms
and provisions of the applicable indenture and debt securities to which any prospectus supplement may relate. Other specific terms of the applicable indenture and debt securities will be described in the applicable prospectus supplement. If any
particular terms of the indenture or debt securities described in a prospectus supplement differ from any of the terms described below, then the terms described below will be deemed to have been superseded by that prospectus supplement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Debt securities may be issued in
separate series without limitation as to aggregate principal amount. We may specify a maximum aggregate principal amount for the debt securities of any series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are not limited as to the amount of debt securities we may issue under the indentures. Unless otherwise provided in a prospectus
supplement, a series of debt securities may be reopened to issue additional debt securities of such series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The prospectus supplement
relating to a particular series of debt securities will set forth: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">whether the debt securities are senior or subordinated; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the offering price; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the title; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">any limit on the aggregate principal amount; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the person who shall be entitled to receive interest, if other than the record holder on the record date; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the date or dates the principal will be payable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the interest rate or rates, which may be fixed or variable, if any, the date from which interest will accrue, the interest payment dates and the regular record dates, or the method for calculating the dates and rates;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the place where payments may be made; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">any mandatory or optional redemption provisions or sinking fund provisions and any applicable redemption or purchase prices associated with these provisions; </TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-15- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">if issued other than in denominations of U.S. $1,000 or any multiple of U.S. $1,000, the denominations in which the debt securities shall be issuable; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">if applicable, the method for determining how the principal, premium, if any, or interest will be calculated by reference to an index or formula; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">if other than U.S. currency, the currency or currency units in which principal, premium, if any, or interest will be payable and whether we or a holder may elect payment to be made in a different currency;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the portion of the principal amount that will be payable upon acceleration of maturity, if other than the entire principal amount; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">if the principal amount payable at stated maturity will not be determinable as of any date prior to stated maturity, the amount or method for determining the amount which will be deemed to be the principal amount;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">if applicable, whether the debt securities shall be subject to the defeasance provisions described below under “Satisfaction and discharge; defeasance” or such other defeasance provisions specified in the
applicable prospectus supplement for the debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">any conversion or exchange provisions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">whether the debt securities will be issuable in the form of a global security; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the deletion, addition or change in any event of default; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">any change or modification to the subordination provisions applicable to the subordinated debt securities if different from those described below under “Subordinated debt securities;” </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">any deletion, addition or change in the covenants set forth in the indenture; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">any paying agents, authenticating agents, security registrars or other agents for the debt securities, if other than the trustee; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">any provisions relating to any security provided for the debt securities, including any provisions regarding the circumstances under which collateral may be released or substituted; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">any provisions relating to guaranties for the securities and any circumstances under which there may be additional obligors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">any provisions granting special rights to holders when a specified event occurs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">any special tax provisions that apply to the debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">with respect to any debt securities that do not bear interest, the dates for certain required reports to the applicable trustee; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">any and all additional, eliminated or changed terms that will apply to the debt securities; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">any other terms of such debt securities. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in the prospectus
supplement, the debt securities will be registered debt securities. Debt securities may be sold at a substantial discount below their stated principal amount, bearing no interest or interest at a rate which at time of issuance is below market rates.
The U.S. federal income tax considerations applicable to debt securities sold at a discount will be described in the applicable prospectus supplement. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-16- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exchange and transfer </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Debt securities may be transferred or exchanged at the office of the security registrar or at the office of any transfer agent designated by
us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will not impose a service charge for any transfer or exchange, but we may require holders to pay any tax or other governmental
charges associated with any transfer or exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event of any partial redemption of debt securities of any series, we will not be
required to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">issue, register the transfer of, or exchange, any debt security of that series during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption and ending at the close of
business on the day of the mailing; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">register the transfer of or exchange any debt security of that series selected for redemption, in whole or in part, except the unredeemed portion being redeemed in part. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will appoint the trustee as the initial security registrar. Any transfer agent, in addition to the security registrar initially designated
by us, will be named in the prospectus supplement. We may designate additional transfer agents or change transfer agents or change the office of the transfer agent. However, we will be required to maintain a transfer agent in each place of payment
for the debt securities of each series. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The debt securities of any series may be represented, in whole or in part, by one or more global securities. Each global security will: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">be registered in the name of a depositary, or its nominee, that we will identify in a prospectus supplement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">be deposited with the depositary or nominee or custodian; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">bear any required legends. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">No global security may be exchanged in whole or in part for debt
securities registered in the name of any person other than the depositary or any nominee unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the depositary has notified us that it is unwilling or unable to continue as depositary or has ceased to be qualified to act as depositary; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">an event of default is continuing with respect to the debt securities of the applicable series; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">any other circumstance described in a prospectus supplement has occurred permitting or requiring the issuance of any such security. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As long as the depositary, or its nominee, is the registered owner of a global security, the depositary or nominee will be considered the sole
owner and holder of the debt securities represented by the global security for all purposes under the indentures. Except in the above limited circumstances, owners of beneficial interests in a global security will not be: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">entitled to have the debt securities registered in their names; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">entitled to physical delivery of certificated debt securities; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">considered to be holders of those debt securities under the indenture. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Payments on a global
security will be made to the depositary or its nominee as the holder of the global security. Some jurisdictions have laws that require that certain purchasers of securities take physical delivery of such securities in definitive form. These laws may
impair the ability to transfer beneficial interests in a global security. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-17- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Institutions that have accounts with the depositary or its nominee are referred to as
“participants.” Ownership of beneficial interests in a global security will be limited to participants and to persons that may hold beneficial interests through participants. The depositary will credit, on its book-entry registration and
transfer system, the respective principal amounts of debt securities represented by the global security to the accounts of its participants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Ownership of beneficial interests in a global security will be shown on and effected through records maintained by the depositary, with
respect to participants’ interests, or any participant, with respect to interests of persons held by participants on their behalf. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Payments, transfers and exchanges relating to beneficial interests in a global security will be subject to policies and procedures of the
depositary. The depositary policies and procedures may change from time to time. Neither any trustee nor we will have any responsibility or liability for the depositary’s or any participant’s records with respect to beneficial interests in
a global security. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment and paying agents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in a prospectus supplement, the provisions described in this paragraph will apply to the debt securities. Payment of
interest on a debt security on any interest payment date will be made to the person in whose name the debt security is registered at the close of business on the regular record date. Payment on debt securities of a particular series will be payable
at the office of a paying agent or paying agents designated by us. However, at our option, we may pay interest by mailing a check to the record holder. The trustee will be designated as our initial paying agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may also name any other paying agents in a prospectus supplement. We may designate additional paying agents, change paying agents or change
the office of any paying agent. However, we will be required to maintain a paying agent in each place of payment for the debt securities of a particular series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">All moneys paid by us to a paying agent for payment on any debt security that remain unclaimed for a period ending the earlier of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">10 business days prior to the date the money would be turned over to the applicable state; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">at the end of two years after such payment was due, </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">will be repaid to us thereafter. The holder may look only
to us for such payment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No protection in the event of a change of control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in a prospectus supplement with respect to a particular series of debt securities, the debt securities will not
contain any provisions that may afford holders of the debt securities protection in the event we have a change in control or in the event of a highly leveraged transaction, whether or not such transaction results in a change in control. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Covenants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in
a prospectus supplement with respect to a particular series of debt securities, the debt securities will not contain any financial or restrictive covenants. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-18- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, merger and sale of assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless we indicate otherwise in a prospectus supplement with respect to a particular series of debt securities, we may not consolidate with or
merge into any other person (other than one of our subsidiaries), in a transaction in which we are not the surviving corporation, or convey, transfer or lease our properties and assets substantially as an entirety to, any person (other than one of
our subsidiaries), unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the successor entity, if any, is a U.S. corporation, limited liability company, partnership, trust or other business entity; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the successor entity assumes our obligations on the debt securities and under the indentures; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">immediately after giving effect to the transaction, no default or event of default shall have occurred and be continuing; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">certain other conditions specified in the indenture are met. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of default </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless we indicate otherwise in a prospectus supplement, the following will be events of default for any series of debt securities under the
indentures: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">we fail to pay principal of or any premium on any debt security of that series when due; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">we fail to pay any interest on any debt security of that series for 30 days after it becomes due; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">we fail to deposit any sinking fund payment when due; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">we fail to perform any other covenant in the indenture and such failure continues for 90 days after we are given the notice required in the indentures; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">certain events involving our bankruptcy, insolvency or reorganization. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additional or
different events of default applicable to a series of debt securities may be described in a prospectus supplement. An event of default of one series of debt securities is not necessarily an event of default for any other series of debt securities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The trustee may withhold notice to the holders of any default, except defaults in the payment of principal, premium, if any, interest,
any sinking fund installment on, or with respect to any conversion right of, the debt securities of such series. However, the trustee must consider it to be in the interest of the holders of the debt securities of such series to withhold this
notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless we indicate otherwise in a prospectus supplement, if an event of default, other than an event of default described in
clause (5) above, shall occur and be continuing with respect to any series of debt securities, either the trustee or the holders of at least 25 percent in aggregate principal amount of the outstanding securities of that series may declare the
principal amount and premium, if any, of the debt securities of that series, or if any debt securities of that series are original issue discount securities, such other amount as may be specified in the applicable prospectus supplement, in each case
together with accrued and unpaid interest, if any, thereon, to be due and payable immediately. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless we indicate otherwise in a
prospectus supplement, if an event of default described in clause (5) above shall occur, the principal amount and premium, if any, of all the debt securities of that series, or if any debt securities of that series are original issue discount
securities, such other amount as may be specified in the applicable prospectus supplement, in each case together with accrued and unpaid interest, if any, thereon, will automatically become immediately due and payable. Any payment by us on the
subordinated debt securities following any such acceleration will be subject to the subordination provisions described below under “Subordinated debt securities.” </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-19- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, each indenture will provide that we may, at our option, elect that
the sole remedy for an event of default relating to our failure to comply with our obligations described under the section entitled “Reports” below or our failure to comply with the requirements of Section 314(a)(1) of the Trust
Indenture Act will for the first 180 days after the occurrence of such an event of default consist exclusively of the right to receive additional interest on the relevant series of debt securities at an annual rate equal to (i) 0.25% of the
principal amount of such series of debt securities for the first 90 days after the occurrence of such event of default and (ii) 0.50% of the principal amount of such series of debt securities from the 91st day to, and including, the 180th day
after the occurrence of such event of default, which we call “additional interest.” If we so elect, the additional interest will accrue on all outstanding debt securities from and including the date on which such event of default first
occurs until such violation is cured or waived and shall be payable on each relevant interest payment date to holders of record on the regular record date immediately preceding the interest payment date. On the 181<SUP
STYLE="font-size:85%; vertical-align:top">st</SUP> day after such event of default (if such violation is not cured or waived prior to such 181<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> day), the debt securities will be subject to
acceleration as provided above. In the event we do not elect to pay additional interest upon any such event of default in accordance with this paragraph, the debt securities will be subject to acceleration as provided above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In order to elect to pay the additional interest as the sole remedy during the first 180 days after the occurrence of any event of default
relating to the failure to comply with the reporting obligations in accordance with the preceding paragraph, we must notify all holders of debt securities and the trustee and paying agent of such election prior to the close of business on the first
business day following the date on which such event of default occurs. Upon our failure to timely give such notice or pay the additional interest, the debt securities will be immediately subject to acceleration as provided above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">After acceleration, the holders of a majority in aggregate principal amount of the outstanding securities of that series may, under certain
circumstances, rescind and annul such acceleration if all events of default, other than the non-payment of accelerated principal, or other specified amounts or interest, have been cured or waived. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Other than the duty to act with the required care during an event of default, the trustee will not be obligated to exercise any of its rights
or powers at the request of the holders unless the holders shall have offered to the trustee reasonable indemnity. Generally, the holders of a majority in aggregate principal amount of the outstanding debt securities of any series will have the
right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee or exercising any trust or power conferred on the trustee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">A holder of debt securities of any series will not have any right to institute any proceeding under the indentures, or for the appointment of
a receiver or a trustee, or for any other remedy under the indentures, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">the holder has previously given to the trustee written notice of a continuing event of default with respect to the debt securities of that series; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">the holders of at least 25 percent in aggregate principal amount of the outstanding debt securities of that series have made a written request and have offered reasonable indemnity to the trustee to institute the
proceeding; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">the trustee has failed to institute the proceeding and has not received direction inconsistent with the original request from the holders of a majority in aggregate principal amount of the outstanding debt securities of
that series within 60 days after the original request. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Holders may, however, sue to enforce the payment of principal,
premium or interest on any debt security on or after the due date or to enforce the right, if any, to convert any debt security (if the debt security is convertible) without following the procedures listed in (1) through (3) above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will furnish the trustee an annual statement from our officers as to whether or not we are in default in the performance of the conditions
and covenants under the indenture and, if so, specifying all known defaults. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-20- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification and waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless we indicate otherwise in a prospectus supplement, the applicable trustee and we may make modifications and amendments to an indenture
with the consent of the holders of a majority in aggregate principal amount of the outstanding securities of each series affected by the modification or amendment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may also make modifications and amendments to the indentures for the benefit of holders without their consent, for certain purposes
including, but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">to evidence the succession of another person to Pacific Biosciences, or successive successions, and the assumption by any such successor of the covenants of Pacific Biosciences in the indentures; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">adding covenants under the indentures; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">adding events of default under the indentures; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">making certain changes to facilitate the issuance of the debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">to add to, change or eliminate any of the provisions of the indentures or more series of securities, provided that any such addition, change or elimination (A) shall neither (i) apply to any security of any
series created prior to the execution of such supplemental indenture and entitled to the benefit of such provision nor (ii) modify the rights of the holder of any such security with respect to such provision or (B) shall become effective
only when there is no such security outstanding; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">securing the debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">providing for guaranties of, or additional obligors on, the debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">to establish the form or term of debt securities as permitted by the indentures; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">providing for a successor trustee or additional trustees; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">conforming the indenture to the description of the debt securities set forth in this prospectus or the accompanying prospectus supplement; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">curing any ambiguity, defect or inconsistency; provided that such action shall not adversely affect the interest of the holders in any material respect; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">permitting or facilitating the defeasance and discharge of the debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">make such other provisions in regard to matters or questions arising under the indentures or under any supplemental indentures as our board of directors may deem necessary or desirable, and which does not in each case
adversely affect the interests of the holders of the debt securities of a series; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">comply with requirements of the SEC in order to effect or maintain the qualifications of the indentures under the Trust Indenture Act of 1939, as amended. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">However, neither the trustee nor we may make any modification or amendment without the consent of the holder of each outstanding security of
that series affected by the modification or amendment if such modification or amendment would: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">change the stated maturity of the principal of, or any installment of principal or interest on, any debt security; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">reduce the principal, premium, if any, or interest on any debt security or any amount payable upon redemption or repurchase, whether at our option or the option of any holder, or reduce the amount of any sinking fund
payments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">reduce the principal of an original issue discount security or any other debt security payable on acceleration of maturity; </TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-21- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">change the place of payment or the currency in which any debt security is payable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">impair the right to enforce any payment after the stated maturity or redemption date; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">if subordinated debt securities, modify the subordination provisions in a materially adverse manner to the holders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">adversely affect the right to convert any debt security if the debt security is a convertible debt security; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">change the provisions in the indenture that relate to modifying or amending the indenture. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Satisfaction
and discharge; defeasance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may be discharged from our obligations on the debt securities, subject to limited exceptions, of any
series that have matured or will mature or be redeemed within one year if we deposit enough money with the trustee to pay all the principal, interest and any premium due to the stated maturity date or redemption date of the debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each indenture contains a provision that permits us to elect either or both of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">We may elect to be discharged from all of our obligations, subject to limited exceptions, with respect to any series of debt securities then outstanding. If we make this election, the holders of the debt securities of
the series will not be entitled to the benefits of the indenture, except for the rights of holders to receive payments on debt securities or the registration of transfer and exchange of debt securities and replacement of lost, stolen or mutilated
debt securities. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">We may elect to be released from our obligations under some or all of any financial or restrictive covenants applicable to the series of debt securities to which the election relates and from the consequences of an
event of default resulting from a breach of those covenants. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">To make either of the above elections, we must irrevocably
deposit in trust with the trustee enough money to pay in full the principal, interest and premium on the debt securities. This amount may be made in cash and/or U.S. government obligations or, in the case of debt securities denominated in a currency
other than U.S. dollars, cash in the currency in which such series of securities is denominated and/or foreign government obligations. As a condition to either of the above elections, for debt securities denominated in U.S. dollars we must deliver
to the trustee an opinion of counsel that the holders of the debt securities will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">With respect to debt securities of any series that are denominated in a currency other than United States dollars, “foreign government
obligations” means: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">direct obligations of the government that issued or caused to be issued the currency in which such securities are denominated and for the payment of which obligations its full faith and credit is pledged, or, with
respect to debt securities of any series which are denominated in Euros, direct obligations of certain members of the European Union for the payment of which obligations the full faith and credit of such members is pledged, which in each case are
not callable or redeemable at the option of the issuer thereof; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">obligations of a person controlled or supervised by or acting as an agency or instrumentality of a government described in the bullet above the timely payment of which is unconditionally guaranteed as a full faith and
credit obligation by such government, which are not callable or redeemable at the option of the issuer thereof. </TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-22- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reports </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The indentures provide that any reports or documents that we file with the SEC pursuant to Section 13 or 15(d) of the Exchange Act will be
filed with the trustee within 15 days after the same is filed with the SEC. Documents filed by us with the SEC via the EDGAR system will be deemed filed with the trustee as of the time such documents are filed with the SEC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notices </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Notices to holders will be given
by mail to the addresses of the holders in the security register. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The indentures and the debt securities will be governed by, and construed under, the laws of the State of New York. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No personal liability of directors, officers, employees and stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">No incorporator, stockholder, employee, agent, officer, director or subsidiary of ours will have any liability for any obligations of ours, or
because of the creation of any indebtedness under the debt securities, the indentures or supplemental indentures. The indentures provide that all such liability is expressly waived and released as a condition of, and as a consideration for, the
execution of such indentures and the issuance of the debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regarding the trustee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The indentures limit the right of the trustee, should it become our creditor, to obtain payment of claims or secure its claims. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The trustee will be permitted to engage in certain other transactions with us. However, if the trustee acquires any conflicting interest, and
there is a default under the debt securities of any series for which it is trustee, the trustee must eliminate the conflict or resign. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Subordinated
debt securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following provisions will be applicable with respect to each series of subordinated debt securities, unless
otherwise stated in the prospectus supplement relating to that series of subordinated debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The indebtedness evidenced by the
subordinated debt securities of any series is subordinated, to the extent provided in the subordinated indenture and the applicable prospectus supplement, to the prior payment in full, in cash or other payment satisfactory to the holders of senior
debt, of all senior debt, including any senior debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon any distribution of our assets upon any dissolution, winding up,
liquidation or reorganization, whether voluntary or involuntary, marshalling of assets, assignment for the benefit of creditors, or in bankruptcy, insolvency, receivership or other similar proceedings, payments on the subordinated debt securities
will be subordinated in right of payment to the prior payment in full in cash or other payment satisfactory to holders of senior debt of all senior debt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In the event of any acceleration of the subordinated debt securities of any series because of an event of default with respect to the
subordinated debt securities of that series, holders of any senior debt would be entitled to payment in full in cash or other payment satisfactory to holders of senior debt of all senior debt before the holders of subordinated debt securities are
entitled to receive any payment or distribution. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-23- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the subordinated debt securities will be structurally subordinated to all
indebtedness and other liabilities of our subsidiaries, including trade payables and lease obligations. This occurs because our right to receive any assets of our subsidiaries upon their liquidation or reorganization, and your right to participate
in those assets, will be effectively subordinated to the claims of that subsidiary’s creditors, including trade creditors, except to the extent that we are recognized as a creditor of such subsidiary. If we are recognized as a creditor of that
subsidiary, our claims would still be subordinate to any security interest in the assets of the subsidiary and any indebtedness of the subsidiary senior to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We are required to promptly notify holders of senior debt or their representatives under the subordinated indenture if payment of the
subordinated debt securities is accelerated because of an event of default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Under the subordinated indenture, we may also not make
payment on the subordinated debt securities if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">a default in our obligations to pay principal, premium, if any, interest or other amounts on our senior debt occurs and the default continues beyond any applicable grace period, which we refer to as a payment default;
or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">any other default occurs and is continuing with respect to designated senior debt that permits holders of designated senior debt to accelerate its maturity, which we refer to as a non-payment default, and the trustee
receives a payment blockage notice from us or some other person permitted to give the notice under the subordinated indenture. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will resume payments on the subordinated debt securities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">in case of a payment default, when the default is cured or waived or ceases to exist, and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">in case of a nonpayment default, the earlier of when the default is cured or waived or ceases to exist or 179 days after the receipt of the payment blockage notice. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">No new payment blockage period may commence on the basis of a nonpayment default unless 365 days have elapsed from the effectiveness of the
immediately prior payment blockage notice. No nonpayment default that existed or was continuing on the date of delivery of any payment blockage notice to the trustee shall be the basis for a subsequent payment blockage notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As a result of these subordination provisions, in the event of our bankruptcy, dissolution or reorganization, holders of senior debt may
receive more, ratably, and holders of the subordinated debt securities may receive less, ratably, than our other creditors. The subordination provisions will not prevent the occurrence of any event of default under the subordinated indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The subordination provisions will not apply to payments from money or government obligations held in trust by the trustee for the payment of
principal, interest and premium, if any, on subordinated debt securities pursuant to the provisions described under the section entitled “Satisfaction and discharge; defeasance,” if the subordination provisions were not violated at the
time the money or government obligations were deposited into trust. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If the trustee or any holder receives any payment that should not
have been made to them in contravention of subordination provisions before all senior debt is paid in full in cash or other payment satisfactory to holders of senior debt, then such payment will be held in trust for the holders of senior debt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Senior debt securities will constitute senior debt under the subordinated indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Additional or different subordination provisions may be described in a prospectus supplement relating to a particular series of debt
securities. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-24- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Definitions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">“Designated senior debt” means our obligations under any particular senior debt in which the instrument creating or evidencing the
same or the assumption or guarantee thereof, or related agreements or documents to which we are a party, expressly provides that such indebtedness shall be designated senior debt for purposes of the subordinated indenture. The instrument, agreement
or other document evidencing any designated senior debt may place limitations and conditions on the right of such senior debt to exercise the rights of designated senior debt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">“Indebtedness” means the following, whether absolute or contingent, secured or unsecured, due or to become due, outstanding on the
date of the indenture for such series of securities or thereafter created, incurred or assumed: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">our indebtedness evidenced by a credit or loan agreement, note, bond, debenture or other written obligation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">all of our obligations for money borrowed; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">all of our obligations evidenced by a note or similar instrument given in connection with the acquisition of any businesses, properties or assets of any kind, </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">our obligations: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%"> </TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">as lessee under leases required to be capitalized on the balance sheet of the lessee under generally accepted accounting principles, or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%"> </TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">as lessee under leases for facilities, capital equipment or related assets, whether or not capitalized, entered into or leased for financing purposes; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">all of our obligations under interest rate and currency swaps, caps, floors, collars, hedge agreements, forward contracts or similar agreements or arrangements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">all of our obligations with respect to letters of credit, bankers’ acceptances and similar facilities, including reimbursement obligations with respect to the foregoing; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">all of our obligations issued or assumed as the deferred purchase price of property or services, but excluding trade accounts payable and accrued liabilities arising in the ordinary course of business;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">all obligations of the type referred to in the above clauses of another person, the payment of which, in either case, we have assumed or guaranteed, for which we are responsible or liable, directly or indirectly,
jointly or severally, as obligor, guarantor or otherwise, or which are secured by a lien on our property; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">renewals, extensions, modifications, replacements, restatements and refundings of, or any indebtedness or obligation issued in exchange for, any such indebtedness or obligation described in the above clauses of this
definition. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">“Senior debt” means the principal of, premium, if any, and interest, including all interest accruing
subsequent to the commencement of any bankruptcy or similar proceeding, whether or not a claim for post-petition interest is allowable as a claim in any such proceeding, and rent payable on or in connection with, and all fees and other amounts
payable in connection with, our indebtedness. However, senior debt shall not include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">any debt or obligation if its terms or the terms of the instrument under which or pursuant to which it is issued expressly provide that it shall not be senior in right of payment to the subordinated debt securities or
expressly provide that such indebtedness is on the same basis or “junior” to the subordinated debt securities; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">debt to any of our subsidiaries, a majority of the voting stock of which is owned, directly or indirectly, by us. </TD></TR></TABLE>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-25- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">“Subsidiary” means a corporation more than 50% of the outstanding voting stock of which
is owned, directly or indirectly, by us or by one or more of our other subsidiaries or by a combination of us and our other subsidiaries. For purposes of this definition, “voting stock” means stock or other similar interests which
ordinarily has or have voting power for the election of directors, or persons performing similar functions, whether at all times or only so long as no senior class of stock or other interests has or have such voting power by reason of any
contingency. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-26- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_25"></A>DESCRIPTION OF THE UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may issue units comprised of one or more of the other classes of securities described in this prospectus in any combination. Each unit will
be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The units may be issued under unit agreements
to be entered into between us and a unit agent, as detailed in the prospectus supplement relating to the units being offered. The prospectus supplement will describe: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances the securities comprising the units may be held or transferred separately;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">a description of the terms of any unit agreement governing the units; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">a description of the provisions for the payment, settlement, transfer or exchange of the units; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">a discussion of material federal income tax considerations, if applicable; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">whether the units if issued as a separate security will be issued in fully registered or global form. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The descriptions of the units in this prospectus and in any prospectus supplement are summaries of the material provisions of the applicable
agreements. These descriptions do not restate those agreements in their entirety and may not contain all the information that you may find useful. We urge you to read the applicable agreements because they, and not the summaries, define your rights
as holders of the units. For more information, please review the forms of the relevant agreements, which will be filed with the SEC promptly after the offering of units and will be available as described under the heading “Where You Can Find
More Information.” </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-27- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_26"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may sell the securities offered through this prospectus (1) to or through underwriters or dealers, (2) directly to purchasers,
including our affiliates, (3) through agents, or (4) through a combination of any these methods. The securities may be distributed at a fixed price or prices, which may be changed, market prices prevailing at the time of sale, prices
related to the prevailing market prices, or negotiated prices. The prospectus supplement will include the following information: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the terms of the offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the names of any underwriters or agents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the name or names of any managing underwriter or underwriters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the purchase price of the securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the net proceeds from the sale of the securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">any delayed delivery arrangements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">any underwriting discounts, commissions and other items constituting underwriters’ compensation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">any initial public offering price; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">any discounts or concessions allowed or reallowed or paid to dealers; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">any commissions paid to agents. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sale through underwriters or dealers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If underwriters are used in the sale, the underwriters will acquire the securities for their own account, including through underwriting,
purchase, security lending or repurchase agreements with us. The underwriters may resell the securities from time to time in one or more transactions, including negotiated transactions. Underwriters may sell the securities in order to facilitate
transactions in any of our other securities (described in this prospectus or otherwise), including other public or private transactions and short sales. Underwriters may offer securities to the public either through underwriting syndicates
represented by one or more managing underwriters or directly by one or more firms acting as underwriters. Unless otherwise indicated in the prospectus supplement, the obligations of the underwriters to purchase the securities will be subject to
certain conditions, and the underwriters will be obligated to purchase all the offered securities if they purchase any of them. The underwriters may change from time to time any initial public offering price and any discounts or concessions allowed
or reallowed or paid to dealers. The prospectus supplement will include the names of the principal underwriters the respective amount of securities underwritten, the nature of the obligation of the underwriters to take the securities and the nature
of any material relationship between an underwriter and us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">If dealers are used in the sale of securities offered through this
prospectus, we will sell the securities to them as principals. They may then resell those securities to the public at varying prices determined by the dealers at the time of resale. The prospectus supplement will include the names of the dealers and
the terms of the transaction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Direct sales and sales through agents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may sell the securities offered through this prospectus directly. In this case, no underwriters or agents would be involved. Such securities
may also be sold through agents designated from time to time. The prospectus supplement will name any agent involved in the offer or sale of the offered securities and will describe any commissions payable to the agent by us. Unless otherwise
indicated in the prospectus supplement, any agent will agree to use its reasonable best efforts to solicit purchases for the period of its appointment. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-28- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may sell the securities directly to institutional investors or others who may be deemed to be
underwriters within the meaning of the Securities Act with respect to any sale of those securities. The terms of any such sales will be described in the prospectus supplement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Market making, stabilization and other transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Unless the applicable prospectus supplement states otherwise, each series of offered securities will be a new issue and will have no
established trading market. We may elect to list any series of offered securities on an exchange. Any underwriters that we use in the sale of offered securities may make a market in such securities, but may discontinue such market making at any time
without notice. Therefore, we cannot assure you that the securities will have a liquid trading market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Any underwriter may also engage in
stabilizing transactions, syndicate covering transactions and penalty bids in accordance with Rule 104 under the Securities Exchange Act of 1934, as amended. Stabilizing transactions involve bids to purchase the underlying security in the open
market for the purpose of pegging, fixing or maintaining the price of the securities. Syndicate covering transactions involve purchases of the securities in the open market after the distribution has been completed in order to cover syndicate short
positions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Penalty bids permit the underwriters to reclaim a selling concession from a syndicate member when the securities originally
sold by the syndicate member are purchased in a syndicate covering transaction to cover syndicate short positions. Stabilizing transactions, syndicate covering transactions and penalty bids may cause the price of the securities to be higher than it
would be in the absence of the transactions. The underwriters may, if they commence these transactions, discontinue them at any time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Derivative
transactions and hedging </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We, the underwriters or other agents may engage in derivative transactions involving the securities. These
derivatives may consist of short sale transactions and other hedging activities. The underwriters or agents may acquire a long or short position in the securities, hold or resell securities acquired and purchase options or futures on the securities
and other derivative instruments with returns linked to or related to changes in the price of the securities. In order to facilitate these derivative transactions, we may enter into security lending or repurchase agreements with the underwriters or
agents. The underwriters or agents may effect the derivative transactions through sales of the securities to the public, including short sales, or by lending the securities in order to facilitate short sale transactions by others. The underwriters
or agents may also use the securities purchased or borrowed from us or others (or, in the case of derivatives, securities received from us in settlement of those derivatives) to directly or indirectly settle sales of the securities or close out any
related open borrowings of the securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic auctions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We may also make sales through the Internet or through other electronic means. Since we may from time to time elect to offer securities
directly to the public, with or without the involvement of agents, underwriters or dealers, utilizing the Internet or other forms of electronic bidding or ordering systems for the pricing and allocation of such securities, you should pay particular
attention to the description of that system we will provide in a prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Such electronic system may allow bidders to
directly participate, through electronic access to an auction site, by submitting conditional offers to buy that are subject to acceptance by us, and which may directly affect the price or other terms and conditions at which such securities are
sold. These bidding or ordering systems may present to each bidder, on a so-called “real-time” basis, relevant information to assist in making a bid, such as the clearing spread at which the offering would be sold, based on the bids
submitted, and whether a bidder’s individual bids would be accepted, prorated or rejected. For example, in the case of a debt security, the clearing </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-29- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
spread could be indicated as a number of “basis points” above an index treasury note. Of course, many pricing methods can and may also be used. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon completion of such an electronic auction process, securities will be allocated based on prices bid, terms of bid or other factors. The
final offering price at which securities would be sold and the allocation of securities among bidders would be based in whole or in part on the results of the Internet or other electronic bidding process or auction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Agents,
underwriters, and dealers may be entitled, under agreements entered into with us, to indemnification by us against certain liabilities, including liabilities under the Securities Act. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-30- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_27"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The validity of the securities offered by this prospectus will be passed upon by Wilson Sonsini Goodrich & Rosati, Professional
Corporation, Palo Alto, California. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_28"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Ernst & Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our
Annual Report on Form 10-K for the year ended December 31, 2013, and the effectiveness of our internal control over financial reporting as of December 31, 2013, as set forth in their reports, which are incorporated by reference in this
prospectus and elsewhere in the registration statement. Our financial statements and our management’s assessment of the effectiveness of internal control over financial reporting as of December 31, 2013 are incorporated by reference in
reliance on Ernst
& Young LLP’s reports, given on their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_29"></A>WHERE YOU
CAN FIND MORE INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and other reports, proxy statements and other information with the SEC. Our SEC
filings are available to the public over the Internet at the SEC’s website at http://www.sec.gov. You may also read and copy any document we file at the SEC’s Public Reference Room at 100 F Street, NE, Washington, D.C. 20549. Please call
the SEC at 1-800-SEC-0330 for further information on the Public Reference Room. Our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, including any amendments to those reports, and other information that we
file with or furnish to the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act can also be accessed free of charge through the Internet. These filings will be available as soon as reasonably practicable after we electronically file such
material with, or furnish it to, the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement under the Securities Act of 1933 relating
to the offering of these securities. The registration statement, including the attached exhibits, contains additional relevant information about us and the securities. This prospectus does not contain all of the information set forth in the
registration statement. You can obtain a copy of the registration statement, at prescribed rates, from the SEC at the address listed above. The registration statement and the documents referred to below under “Incorporation by Reference”
are also available on our Internet website, www.pacificbiosciences.com. We have not incorporated by reference into this prospectus the information on our website, and you should not consider it to be a part of this prospectus. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-31- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="suprom402129_30"></A>INFORMATION INCORPORATED BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference into this prospectus certain information we file with it, which means that we can disclose
important information by referring you to those documents. The information incorporated by reference is considered to be a part of this prospectus, and information that we file later with the SEC will automatically update and supersede information
contained in this prospectus and any accompanying prospectus supplement. We incorporate by reference the documents listed below that we have previously filed with the SEC (excluding any portions of any Form 8-K that are not deemed “filed”
pursuant to the General Instructions of Form 8-K): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">our Annual Report on Form 10-K for the fiscal year ended December 31, 2013, including the information specifically incorporated by reference into the Annual Report on Form 10-K from our definitive proxy statement
on Schedule 14A, filed on April 16, 2014; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2014, June 30, 2014, and September 30, 2014; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">our Current Reports on Form 8-K filed February 4, 2014, April 30, 2014, May 23, 2014, July 24, 2014, August 28, 2014 and October 23, 2014; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt"> </P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"> </TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">•</TD>
<TD WIDTH="1%" VALIGN="top"> </TD>
<TD ALIGN="left" VALIGN="top">the description of our common stock contained in the Registration Statement on Form 8-A relating thereto, including any amendment or report filed for the purpose of updating such description. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference into this prospectus additional documents that we may file with the SEC under Sections 13(a), 13(c), 14
or 15(d) of the Exchange Act prior to the completion or termination of the offering, including all such documents we may file with the SEC after the date of the initial registration statement and prior to the effectiveness of the registration
statement, but excluding any information deemed furnished and not filed with the SEC. Any statements contained in a previously filed document incorporated by reference into this prospectus is deemed to be modified or superseded for purposes of this
prospectus to the extent that a statement contained in this prospectus, or in a subsequently filed document also incorporated by reference herein, modifies or supersedes that statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This prospectus may contain information that updates, modifies or is contrary to information in one or more of the documents incorporated by
reference in this prospectus. You should rely only on the information incorporated by reference or provided in this prospectus. We have not authorized anyone else to provide you with different information. You should not assume that the information
in this prospectus is accurate as of any date other than the date of this prospectus or the date of the documents incorporated by reference in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">We will provide to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, at no cost
to the requester, a copy of any and all of the information that is incorporated by reference in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Requests for such
documents should be directed to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Pacific Biosciences of California, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1380 Willow Road </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Menlo Park,
California 94025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Investor Relations </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">You may also access the documents incorporated by reference in this prospectus through our website at www.pacb.com. Except for the specific
incorporated documents listed above, no information available on or through our website shall be deemed to be incorporated in this prospectus or the registration statement of which it forms a part. </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-32- </P>
<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000"> </P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000"> </P> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Shares </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt"> </P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">
<IMG SRC="g402129g75i77.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>Pacific Biosciences of California, Inc. </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt"> </P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:39%"> </P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt"> </P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:39%"> </P></center>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><I>Sole Book-Running Manager </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Cantor Fitzgerald & Co. </B></P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>, 2017 </B></P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt"> </P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000"> </P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000"> </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g402129g49c21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g402129g49c21.jpg
M_]C_X 02D9)1@ ! 0(!>@%Z #_X3]9:'1T<#HO+VYS+F%D;V)E+F-O;2]X
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@ 8 $U P$1 (1 0,1 ?_$ !X 0 " @, P ("@<)!08+
M @,$_\0 4! 8" 0(% ,(#@,1 0(#! 4&!P@ "1$*$A,4(146(B,Q
M-SAXE[:W%Q@9&B0R05%76'9WEM96U-4F,S4V0D-455EUDY2TM='7V/_$ !X!
M 0 !! ,! 0 " 0,%"00&" <*_\0 2Q$ 0,# 00%" 8&!@H#
M 0(#! %$08'$B$Q"!-!46$4(G&!H;'1\!4R4G*1P0DC,T)BLG-VHK7A
M\18D-38W=8*2M,(T0V/_V@ , P$ A$#$0 _ +_'%*<4KI>0LC4+$M.G,@Y.
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M?8STQI\H9M(90!/*66RMEA(L-#K\LJSHM><E*(@HRL=QC92==D,":J2M%B@
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MDA 'MYCBU$I ^T80* B"G5.?9]H^-;B,MFDDW(DHYAYAJ'IR,!.-$UT%7<'.,XZ7:)N$%'+)(BZ1CJ@00<$8-8-
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M***F$ZJAU#B!0$ZAC',(%*!"@)C"(B!2E*4H=_@H ? '%42E*1NI2$CB<)
M XDD\!PXDDGO))KX<56LD8@N.5*%DRE6?",[;:[E9C8(U*C2-&7?(VDU@?.
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MLC.S-H#,C&T88LB8'$I72=IBCRM61$HB!#F-D"NU \WV@3%7T_MB!36X2]R
M0CN7E!]8R/[0%=UZ7>E&]4;#=3O!H.3-,/6_5$%1'%LV^2(]Q5G&0/H:;<N7
M J"<\!D>B5S/5I1IQ2G%*KX]<U))>U:1(K)IK(K6[*"2J2I"J)*I*26&2*)J
M)G 2G3.41*<A@$IBB(" @(ARXWV^K\Z@OEZ_R-;K_P!KW@/^@_$'YM*9_L7D
M,GO/XFIU^*0UJUTE6:\?)X#PN_9.2&37:NL7TE9%4A@$! Q#P8AW["/8P=C%
M'Y*(" #QD]Y_$TP#S&:T#[QX8B^F=L3@S:S6@CVI4RUV)_#W;'31^[5A!,Q,
MP?SE>:E=+JJ&K5W@%G_DAW*JZ->F8@DE#J-0"*0B9I.\"#\_Y5;.4G(Y'P]G
MS_C6[[;_ &'CM==8LD9I;N4#2+"K@A1"*^4Q9*XV@J<93R%;G#S.$$I)\VE)
M!$I1.6)8OUC 4B)S%@!DXJ9.!FJT]NU(NN"-)]=-[81610S,SRPVRM:Y%RHY
M7<-:K<I&(<XNDWXJ* "J#:4@8B26$P)N'CC)SQL]5<)-D 1NYRHI[,?Y_/A5
MO!P%=N<\NSY[QCVYM8X7RE YMQ/CS+59.487(%3A[*V1!0%3L%I!HF=_$.#E
M %[#2(.XE\4 #R/&2Y/^3RR>'"KH.1FL';Q;4Q.H. +)E)=NUE+4Z70JV.H
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M0*4H"(B (\5;7]=7WE>\U4*V[SSL=XBKJ:Q>H6OEK=5[5''EDGOJ<I_#%J;
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M@,,1FZGV.XNA=>+%LA$H)-4<DY9U(R(Z;(E B1)1[9*C695<" "LB_JKB5
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M>P@$<17JB\[)7Y[J<4IQ2J^?7*,4EMT?.<Q2$)<,GF,8P@4I2ED\,B8QC#V
MI2@ B(B( !W'EQOM]7YU!?+U_D:WP_7RC_Z9U3_ !%$?ZYRW4Z_%(Y.QK$,
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MVZ2:*"")"I(HHI$ B2229 *1--,A2D(0@ 4A0 I0 .6ZN5]O%*<4KH-3Q1
MBV@RT]/47&U!I<[:517L\U4Z=7:Y+6-<SE=Z*T](P\<S>2ZHO'3EV*D@LX.+
MEPNN(^JLH<S-,5Y_WB[C 7J#:^&'[Q=/*D8>W\P9MSB(\5R&>*5#YY58$_?3
MW2G_ .N\^_F;7_S#Q5OJG/L^U/QK%N6_%E=/"I5*3?8HH>P>7+M[-<8"N.*?
M T"O+R0$,+9.Q6J;LSU]#QIU JSR'JUG>) 8!)&*_:$JJAE9YX'K^&:A7T!
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M* &$D6\L.05 *<3?,J'I^3RG\ZK[!^L.\ _E[<U;'Z>&5Y;.6A^G>7+"Z5?
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M444S Y(0P"9!>^1Y4E ?DIQ;5=NN!1^\/IK)F[?>, _/&^?#V_&FX/&IF8Z
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MJQFAFT3:LA/LLUI0""1JYA,M$3OWE8? +2*EIR5K_8H 1)Q#N&Y>Y40$>OR
MD;C[@["K?'H5YWO)%;UNC9JMO6&Q/0-P#@7)MUE9TY.&<N(E:<)L^7O_ -)$
M:)'F9/%2)*%GBJH=:^_A[PA_>]C7],X7EIO]HW]]/\PKZ9K7_<W5O]6;]_=4
MJK3WBC:;;Y=GI]<(FJV.4J=5;YU96>SQT))O:]7'DZXP^:$:STRV;*QT0XF"
MQ<F,4C(.6ZD@$<^%H5;VCCT\C<@?U2L' WP3C@"=W&3V9[.^M?/Z/^Z6V,[M
M,MLFX08]QN*M(.V^ _+8:FSFXB-3"6Y#BK<2_)1&,B.)"F4+#/7M=84]8C-0
M/F+K994T]1>GYM3NS:&$'@_&,R]KBKPC:;RC86CR"Q;5D 4 CES,7!PU,R<.
M&I/.K]!019BRO")J!'PSHQ#@6\TPZ\<(3D=JCP2/2?AD^%?+-I.V?9YLJM[T
MO5E_BM3DM%R)I^$XU+U!<%[N6T1K8AP.MH<.$^62S&@-%2>NE-@C-LK(=MUW
M\/UHJOC+'TU%WK:_*K)U(1:[QNV)/7O(*[,T6;(UBARK.5H/%&.P$Z5=@EUS
MHOUT/H1!VYG)RS6 F346X+.ZGBXKB.]2N6\>Y([!RSPYDFM<UDMNMNF7M<3?
MKU%D6G9WIYUMB2EIQPP[/9D.>4"R0I)2A,O45ZX*FRT)"V4+\K6VW$B0(9HZ
MS<U+629EK%/R+N7G9Z3?S4U+2"YW+^4EI1TJ^D9%ZY4$RCAV]>+K.7*ZAA.J
MLJ=0XB8PCS#$DDD\2>)/B:VR18L:#%C0H;#<:)#CLQ8L9E ;9CQH[:6F&&D)
MPE#;32$MMH2 $I2 . KN,OB'+%?:Q#Z>QAD2$96"+C9N!>2]*LL:UFX69:(R
M$1+Q#A[&(I247*L'+=[&R#,ZS1\T71<M55452'-(I4,$I4 >(R#Q'/([^=8R
M+J73DUR2S#O]DENPY#\28U%NL%]R+*BN*9DQI*&GUJ8D1W4+:?9="7&7$*0X
ME*DD"16 >GGNCLU,L8K$6NV2Y=D]6334MTY7'U/H,>F8P>HO(7BU)1%:2!%/
MS+BT1D5Y)PF0Q6+%TL)$CW$,/.'S&U'Q(PG\3@5TG6.VG9;H.*](U)K:PQG6
MDJ4FVQ)S-SO#Y X(9M-N5)GJWE81UBF$,(4H%UYM&5"V)JAI=JUT-,)V+;';
M+($!;,^24&YA6K^(2!<K!=XW]8^+L%0<F#*5L5DL"B94)RW/6\6<T4F<[M&I
M51O8'3_)M,MPT%UU0*R,9QRS^ZD=I/:>[N&<ZZ=HNU+:#TM-5P=G6SJS3+=H
MYB6B4XS)5N%Y#2]T:@U;+8ZV/"@PDJ*XEM:<D 2% -JN-Q7";9J/;L[=9"W?
MV*N^?\A@#!>?51BJC54'*CJ.HM#B#+)UFHQJQR)>L5@@LL\E'Q6[4)BPR$S-
MF:-5)(Z">+>=4\X5J[> '8E(Y ?GWG)[:V0[*=FUEV3Z)M.C;*>N3#2J1<KB
MML-OW>[R0E4^Y/I!5N%Y:4-1V2MSR:$S%BAQQ+ 69I]";"3K,W4CPR\,T,Y@
M,.,[1FBR* 03 U2JD4>,JRXF'[!#!D&P4\/M?(D]3R!Y@ Q;L)&_(1W(RL^K
ME_:(KY;TNM5MZ7V&ZH:#H;F:G=M^EX*20"XJX2!(N",<R/H6%<^7)6[G@>/H
MF<SU:3Z<4IQ2J^O7(_XWZ/?VRR;_ .YX9Y<;[?5^=07R]?Y&K!7+=3IQ2M+7
M6ESG(UK"]+UOI9EW=[V&L[)BYC(\?/(*TZ DH]46*::8@LFO9K:XKT6S 1*G
M(,VD\R$%">L4)H''/8*BL\,=I^?\*V4ZNX2CM=-?\68;CP0,K2ZJR:SCIN
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MK_Y XJUU:_LFN L_B$.D'6(.0FS;B5Z>,Q;J*I0U8QYEZ:G))8I1%)E'LD:
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MR VQJ'-_TX'% (^F848-W:$V"?.=GVMAB6V E*;0^,E;R0:D^OOX>\(?WO8
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MFHZ@8 88W+[4S&.ON57D=.R,0U\GI(FA,;UM-.LQSYF4"G9JRMELT04_9-Q
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M#)1\0Q1CV#1E"36-GSJ.:MFS=%!%(\[)F(D4H"H82]S91-Q 2 6>(P O P!
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M-)*-P3CYU&V'-US;E5;D1@_7,HSI$*^ (%MNQFR\?'^0YE(B+3EK(=)<L21
MF\Y$9@ON8_<3@K/AV#TJ]V3V5\#Z0NVNW;&M%OS&G&']77IM^%I2UK*5E4O<
M"7;M*:XGZ-M0<0\]O )DR#'@I4@R"ZUZ/=>K\)4X"$JU9BF,%7*U$1L! 0D8
MW3:1L/"P[-&.BHN/:I 5)LRCV+=!HU;IE!-%!)-,@ 4H!S/@ # P .P#D
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MDLN,9!R99R7$>4E9:?H@+'$3%;5V]LTI.X5UF0 J;2>B[PJJJH(_2S!LF1$
MN/=MZ3Q95N_PJR4^H\QZ#GTBO>>S+IV7FVM1[9M1L1O[+82V=2:?3&AW?=&
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M)C&$<@ $@ #D!P KPI<KE<;Q/E72[3I=SN4YY4B9/GR'9<R4^OZSLB2^M;
MKKAP 5+6HX '( 5V/E:X5.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3B
=E.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5_]D!
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g402129g53x69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g402129g53x69.jpg
M_]C_X 02D9)1@ ! 0(!>@%Z #_X3\E:'1T<#HO+VYS+F%D;V)E+F-O;2]X
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M(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!# $! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P 1" !6 84#
M 1$ A$! Q$!_\0 'P @(" @,! D("@8'!0L! P0"_\0
M3! 00" 0,"! (#"! $!P ! (#!08!!P@ "1$2$PH4%2$6(B,Q.1<9)#)8
M=Y>W&!HS-S@Z05ES=7B6L[;6US1TD[@E45=VI;75_\0 '@$! (" P$! 0
M $" P0%" D'!@K_Q !&$0 ! P(#! 8( @8(!P$ ! (#!!$%
M!B$'$C%!$U%A<8&Q""(RD:'!T? 40A4C4G*RX3,T.%-B=(*V%B0UDK7"\=+_
MV@ , P$ A$#$0 _ +_'1$=$2[^<7<^XI\"HK(^V+<[8=F&@X-@-,T3 DUL&
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M)4: 7'EP^_)'$W '/[T^MN[53?XZ<->/O&"L1D%K2@0:9D45EN5OTU' RE\
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M/TB-B68JAE+AFTC+?XB1P9''B51/@9D>=&LC=C<&'-D>XZ,8QQ<]Q#6@D@*
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MX$<EJIMJ'>D#Z!*O"U?<E+&=SEBW:].+;^H^T*M:&%6.N*S^(*H6I3*V98/
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M)K_@;QZD>P>_Z(?:;X^2_''M";)WH.8<Q-_II"IZ>AXRNL/?? :H_3$<HD1
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M;%5D671A<@B4A"AI2(;G[$B*@!U9>'9DX[\2XRZX-&'M]6:.)/ ??WX*KCP
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M)QYCZ\^EH<5AUU>?XJ<^,]2 7$ DDV &I)/(+3Q#$*#":*JQ+%*VEP[#Z*%
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MJ'DO['M3*V0*RV6-D0D:HQ))4@Z*_P#(J5$)EB"L*'ADXC(.-KT>^:$4+KZ
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M:UZK6?UF7O;_ -7)>BA_9^V=_Y7'O\ =>.I4W6LNQ"=1VD>U!L7FWL^L[,V
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M&,1H#);<N7B+V/WU)Z_P^NXZ_N/M,\4WH<T=^3UG 6/3EM :<0M^%G]?VJ7
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M:8U"U:IB0$#7HEHN2),D2FXV) $#02>84:^EG#I1+[ZG'5%$?MM[Uƒ]D
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M?T9283Q:X$<OO4*.?-3O2;^[R&M++P1[8_#3=I\7N!R,KVT-EW,6'Q+1M/\
MJ89Y4(8U6I"<U_K6%F71!A;%=;EL1P/$$\=#BQXQ<DQ),%(C#"'/<--0!S]_
MT5CWM[=LJD<4>VS#\$-K)B=CLWNH7MCD*Z'[Z8*UV/;HY;-XCH=YUH8S$3#1
M)8E1K\NH<"2)!@ )Q8T=(D+8'+&YY<[>X<+=EN"JSU..[B7PR/(/9SL5JFP\
MI^W=LZ=1*E3D>B18K[P8F5L0-AD['#Q4TQIG<D/#J;A+ U885=2O@8?M 8E&
M(R#EZP67U90-;/&FO/ROKU<$QV6^+UX3)J*RJSQGY4S&PUBXP'5)434\+57Y
M12/#8;EU V-8YEL-Q_*6DFLZ_**RG.5XB\J\-**O0.ZVVZ]?I\U&GA1PVYL]
MY+N$4_N<]P?6DCI?C=J0VO2^C]/6"-E(;-H%ILF_8=>4^JUVPLCSAE !L9/X
MVO\ L"PQPH6Q9)]Z%K@+L-*$M4TI<YK&EC#<GB=//KY=G85[OC"ZK9[,KMY_
MARN3U@^23RN^<^B0\A*_*?,9XW?+_,_(#O\ L>_[#WL^[Z/=]EWT>KVU^"B
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MQQST5%VB6G(TL,;]PZ\#H?JE$<8/B2]V<)X**XQ=V/BCOAO:&M &*ZULV B
M(K9%MB(E"0 #KC2-AR%/AK+)Y88;4YL6M7;,;;V5,RF8QTMTB8E2N8@[UHR-
MT]=]/AYKF.37Q)&U>:U8F.,/:;XG\A)/<&T(PBL+V39H.))NE&BIEM4=(RM2
MINNYJ[QD3)I&(>4+L&TW2,AZ7[:YDB-><9;,CB"(-U>X6ZNOR3A>Q/VJCNV5
MQKGOW4'HJ1Y+[YD86U;B?B"6I*-J,?!"<W6$9+LY4Q+IJJ9B<D9V8#RH*1
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6>,8QC'VQC&/MC&/MC'1%YZ(CHB__V0$!
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g402129g75i77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g402129g75i77.jpg
M_]C_X 02D9)1@ ! 0$#P / #_[1<T4&AO=&]S:&]P(#,N, X0DE-!"4
M ! .$))300Z $G $ $
M MP<FEN=$]U='!U= 4 4'-T4V)O;VP! $EN=&5E;G5M
M $EN=&4 0VQR;0 ]P<FEN=%-I>'1E96Y":71B;V]L MP<FEN
M=&5R3F%M951%6%0 B %P 7 !0 $@ 6 !& $( 50 M $T 5P!% "T 1@!0
M #$ , !< $$ 6@ P #$ -0 Q "T > !E '( ;P!X "T ,@ S /<')I
M;G10<F]O9E-E='5P3V)J8P P 4 !R &\ ;P!F " 4P!E '0 =0!P
M *<')O;V93971U< $ 0FQT;F5N=6T ,8G5I;'1I;E!R;V]F
M "7!R;V]F0TU92P X0DE-!#L BT 0 0 $G!R:6YT
M3W5T<'5T3W!T:6]N<P !< 0W!T;F)O;VP $-L8G)B;V]L
M !29W--8F]O; 0W)N0V)O;VP $-N=$-B;V]L !,8FQS
M8F]O; 3F=T=F)O;VP $5M;$1B;V]L !);G1R8F]O;
M 0F-K9T]B:F, ! 4D="0P , 4F0@(&1O=6) ;^
M !'<FX@9&]U8D!OX $)L("!D;W5B0&_@
M 0G)D5%5N=$8C4FQT 0FQD(%5N=$8C4FQT
M 4G-L=%5N=$8C4'AL0':][Z *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M %!G4', 4&=00P !,969T56YT1B-2;'0
M !4;W @56YT1B-2;'0 !38VP@56YT1B-0
M<F- 60 !!C<F]P5VAE;E!R:6YT:6YG8F]O; .8W)O<%)E
M8W1";W1T;VUL;VYG QC<F]P4F5C=$QE9G1L;VYG UC
M<F]P4F5C=%)I9VAT;&]N9P +8W)O<%)E8W14;W!L;VYG X
M0DE- ^T ! #P $ 0/ 0 !.$))300F .
M #^ X0DE-! T 0 >.$))3009 $ 'CA"24T#
M\P "0 0 X0DE-)Q H 0 !.$))30/U
M !( "]F9@ ! &QF9@ & ! "]F9@ ! *&9F@ & ! #(
M ! %H & ! #4 ! "T & !.$))30/X !P
M #_____________________________ ^@ ____________________
M_________P/H /____________________________\#Z #_____
M________________________ ^@ #A"24T$" $ $ ) "
M0 X0DE-!!X 0 .$))300: ,U !@
M !20 !"L 0 !
M 0K !20 ! !
M ! ;G5L; ( &8F]U;F1S3V)J8P $ !28W0Q
M ! !4;W @;&]N9P 3&5F=&QO;F< $)T;VUL
M;VYG !20 !29VAT;&]N9P !"L &<VQI8V5S5FQ,<P %/8FIC
M 0 !7-L:6-E $@ =S;&EC94E$;&]N9P '9W)O
M=7!)1&QO;F< !F]R:6=I;F5N=6T ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960 5'EP965N=6T *15-L:6-E5'EP90 !)
M;6<@ !F)O=6YD<T]B:F, ! 4F-T,0 0 5&]P(&QO
M;F< $QE9G1L;VYG !"=&]M;&]N9P 4D 4F=H
M=&QO;F< 0K W5R;%1%6%0 ! ;G5L;%1%6%0 !
M 37-G951%6%0 ! &86QT5&%G5$585 $ YC96QL
M5&5X=$ES2%1-3&)O;VP! "&-E;&Q497AT5$585 $ EH;W)Z
M06QI9VYE;G5M #T53;&EC94AO<GI!;&EG;@ =D969A=6QT "79E
M<G1!;&EG;F5N=6T /15-L:6-E5F5R=$%L:6=N !V1E9F%U;'0 +
M8F=#;VQO<E1Y<&5E;G5M $453;&EC94)'0V]L;W)4>7!E $YO;F4
M )=&]P3W5T<V5T;&]N9P *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F< "W)I9VAT3W5T<V5T;&]N9P
M.$))300H , C_P .$))3001 ! 0 X0DE-!!0
M 0 '.$))300, SG 0 * Q !X 6^ S+
M !@ ?_8_^T #$%D;V)E7T-- +_[@ .061O8F4 9( !_]L A ," @(
M"0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,
M# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1
M# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P 1" Q * #
M 2( A$! Q$!_]T ! *_\0!/P 04! 0$! 0$ P ! @0%!@<(
M"0H+ 0 !!0$! 0$! 0 ! (#! 4&!P@)"@L0 $$ 0,"! (%!P8(
M!0,,,P$ A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/P
MX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6U
MQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$ @(! @0$ P0%!@<'!@4U
M 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086
MHK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,! (1 Q$ /P#U.RRNJMUMKA77
M6"Y[W$!K6@;G.<YWT6M7GW7O\8F3<]U'1!Z-(,?:WME[_P"5358-M3/^-;ZG
M_!U)?XQ>O/MR!T2AQ%%(;9F08W/,654N_D5-VW._E^G_ *)9)^J5]( ZCU'
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M(0 50 $! #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\
M< !, 00!D &\ 8@!E " 4 !H &\ = !O ', : !O ' ( !# %, -@
M $ .$))300B $N34T *@ @ !P$2 , ! $ $: 4 !
M 8@$; 4 ! :@$H , ! ( $Q ( > <@$R (
M 4 D(=I 0 ! I - -X6V G$ WA;8 "<0061O8F4@
M4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-SHP-CHQ," P,3HS-#HR.0
M Z ! , !__\ * " 0 ! $*Z # 0 ! !20 &
M 0, P $ !@ 1H !0 $ $> 1L !0 $ $F 2@ P $
M @ @$ ! $ $N @( ! $ $@ ! 2
M $X0DE- _T @ /_A 3!-30 J " ' 1( P $
M 1H !0 $ !B 1L !0 $ !J 2@ P $ @ 3$ @
M !X !R 3( @ !0 "0AVD ! $ "D T \ ! #
MP %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$W.C V.C$P
M(# Q.C,T.C(Y #H $ P '__P H ( ! $ 0KH , ! $
M %) 8! P # 0 & !&@ % 0 1X!&P % 0
M 28!* # 0 " " 0 $ 0 2X" @ $ 0 #
MP $ / ?_A0(!H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
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M 0$! 0$! 0$! 0$! 0$!_\ $0@ 5P$: P$1 (1 0,1 ?_$ !X 0 " P #
M 0$ )"@<("P0%!@(#_\0 3! 00" @$"! ($!@H3 ! (#
M!08!!P ("1$2"A,4(146(B,Q.3)!479WMA<9)#@Z0E=A<;<8&B4V-T9'66)U
M@8>1E)>AQ]?A_\0 '0$! $$ P$ $"!08( P0'"?_$ $X1
M $# P("!@4'" 0-!0 $" P0 !1$&(1(Q!Q-!46'P"!0B<8$5(S*1H;'!
M,T)2<K71X?$U-W-U%B0E-#A#4V)T@H.2M$1CHJ.S_]H # ,! (1 Q$ /P"_
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MHFE25H[A2EO&N55$TD%AM*<J<>+^2TVG'JM:<9QGG(Y FM#*XKX',D-J4
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MM2U*Y4[L/9M31D=IR MM=K;U<AM>:RM@IAP5RO>P9-V:7)7.49?)8F!@E!,
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MV9"0DP=+V5#W" J4Y!9?F+P.UR4Z\XH\RI1)W-:SBB%&O?3A#$%OY;?>^0*
MRX0]\D5APHEWY;25K^6.,R\0^OV^UEAIQYS*6T*5CKUG#CC;2>-U:&T<2$\3
MBDH3Q.+2VA/$H@<2UJ2A SE2U)2,D@5X_%5U^D(6ZM#;:%...*2AMM"<K6M:
M\X2E"$IQE2E*5G"4I3C.<YSC&,9SGBH)"05*( )))P !N22=@ -R3RJUEXD
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M '%K';71/YZ%7QGIQ2G%*@H\>?[R+R-?R?FZV?QX_BVK+_Q?MQ^W_P!^5GZ
M]_[ZCM/?[CV^/(\OLJ=?E%36&NQ4-5;!H/=$1>&0WJD7JZ\YG_KTMY&'CQZW
M(E.G94Y]F7H[+"3Q2DY0Z(4,R4PXV\RVM,C8C%*AZ\6.Z\Z3\;VZ=JWEQQRK
MZLV)L&0K(Q+OR4GMYJ=', KT<MS*48S-WF7(C!<I7A"I64=1GVKPO.:E#*L=
M^///N]WXF/X_?^/.O8]%>HQ.[^EW8J[;7PV]L3N\;9['F</'_7QXH,C)'4F:
M]J_F.MH5?7)&WMH:RELJ.5#>B5H:97P2 1C\WR?/WU-94\.FZ)6Q:5N/7.\?
M.#V'ULMAU;?BSE^A[55E9&36$,M*\86XY7K&%8X%]*,N)"#8AF5J1AYE*H5S
MSV'<?4*@<O=D?;M]F*])YA]LV[-3TSU.UR0ZU;.S-U%AI7 KRFWWZ\),0D3&
M0+RF\X>;%L]JG([#ZT9RD@&!D0'DK'+>0J4 ;D\AY\^^ASV8SX]WA4FG7C0]
M(ZVZDJ.I*&"P/&5V/9Q)R21VV3K-8GF6OQNSRZT8RI^2F"T*>7E:UI%&2+'"
M_+!"%8:I)R<U/+85FSD4K0#R(]-$]P],LPE717H[;U/F 9C7=FGG2 !1FR#!
MA[+!R,H #(GL1,I$?,+2RT&2C,W%PSRVT);6ZB4G!S2M@=<0FR*UUJKU;V](
M1DOLNO:K<@KC,0YQ4F!,2T1!$1ZY=L\T&-**?E&!F3S77@1U9.((QA*DXPM4
M'&=N5*HO_!(^O]E7R$>O^3[KS_6/;'^C_-Q5:\[9\?/9X5T'N*HKGT?&E1VI
MI[=W0J!I8,=,=G92J;3BK5$5X9LZY2&NY.Q44744=+A@H=DRDG7)[9#%)$6T
MXX02[9&PD*4XK"E5HVR>SQ[_ '^>=62/*77+G3OA^.Q51V,0Z7L*K=$*K7+V
M6^3DQ\FYP=3I\99R'C,Y7DIU^<%.<<)RI7SUJR[E6?=Z\52.8]XJ,CX.RPP]
M1\5O92UV(]F+KU8[?;1L,Y*$YS@>.AH70^C)*4/(5CURED,(9\AW.,9REMM7
MVXJ5\_/GGFH6?$-I5_S[^:?L/W8[81F;EI/4$BG;I>N;!C,I724FSK]<ZUZ1
MD8]]3@CU,K=?@Y":FHYS#P-DS12HV:#.'M<PXM4GV0!VGGO[OOQ]X%=*8<=@
M1AD45ED889EL<<<=M#+ [#*$MLLLLMI2VTRTVE+;;;:4H0A*4I3A.,8XJBL7
M;RT=JCLIJ6]Z,WA2(38FK-DP!E;M]2L J209&/+3C*'F5_HD1TM&DH8DX.;C
MG19:"F! I>),#D0AB6E*Y[_AWLEY\,_Q!^WO&K8[/*2&D=W7:4TLWF6>4TQ+
MN'0;VR.JVR7P&DH$5;9:(EXFEG?2)P(PO8D\UA;R0!O8JL^T.+M'/R>7PS5R
M&V^*JC&V6^$ZTW-=]24/9D_7;-8*-%433=T,I<O5]MF[[B'='7G85"LMGU8
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M#L70@>D:E@CUG5#3]8+)7 %>U;+4U99!U+!5PM"!G%L(E3V!@8]MTE$##PR
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MAC(2YUIY[!H%8/\ W 9VR1[CFGI*WU%AZ&-9.%7"]=(L6Q1T\0!<7=IC$9]
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MO/I^W]GYCVQ_+_'_ /G%5K[/CCGR^/;_ KH/<5150'XP_LSHRM]"*7U;E;#
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MD!*&VFT)2AMM"0E"$A*0 *EF\:VW/&3KVI[.KG?'5$_?;);K%"/U6Q8J#E@
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MT/\ X= 2+S/R7#H2-..E32YAMG/TC$],R)3PHS;/X/'PB\+PH5'&!L-^7O\
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5G%*<4IQ2G%*<4IQ2G%*<4IQ2O__9
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>